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ABSTRACT
An acute severe exacerbation of asthma is characterised by the release of 
inflammatory mediators, reduction in airway calibre and ultimately hypoxaemia. The 
initial management of such patients includes the administration of high concentrations 
of inspired oxygen and both nebulised and intravenous bronchodilators. Little 
however is known about the influence of oxygen tension on the responsiveness of 
airways to hronchodilator drugs and to bronchoconstrictor stimuli. Recent studies 
undertaken in our own laboratory have suggested that acute alterations in oxygen 
tension have profound effects on responses evoked by bronchodilators and 
bronchoconstrictors in isolated bronchial rings. Similar findings have been made in 
animals. Such observations in man may have relevance to the management of 
patients with acute exacerbations of asthma. The purpose of our studies was to 
investigate the influence of acute alterations in oxygen tension on hronchodilator and 
bronchoconstrictor stimuli both in-vitro in man and in-patients with asthma.
Our initial in-vitro studies suggested that the ability of salbutamol to relax human 
bronchial rings is significantly attenuated by hypoxia (0% tension 4%) when compared 
to normoxia (O2 tension 20%) and hyperoxia (O2 tension 95%). We also found that 
acute hypoxia (O2 tension 4%) significantly attenuated the ability of both histamine 
and methacholine to constrict human isolated bronchial rings when compared to 
normoxia (O2 tension 20%) and hyperoxia (O2 tension 95%). In-patients with mild 
asthma we found that hypoxia (Fi0 2 15%) potentiated and hyperoxia (Fi0 2 100%) had 
no effect on methacholine induced bronchoconstriction. In a series of studies we have 
also found that airway responses to both inhaled histamine and salbutamol were 
unaffected by both hypoxia (Fi0 2 15%) and hyperoxia (Fi0 2  100%) in-patients with 
mild stable asthma. We would conclude from these studies that acute alterations in
ambient oxygen tension have significant effects on airway responses to constrictor 
and dilator stimuli both in-vitro in man and in-patients with asthma. The finding that 
hypoxia potentiates both salbutamol induced relaxation in-vitro in man and 
methacholine induced bronchoconstriction in patients with asthma may have 
relevance to the management of patients with acute exacerbations asthma who as part 
of their routine treatment receive high inspired oxygen tensions and both nebulised 
and intravenous bronchodilators. Further studies may determine the mechanism of 
these effects and lead to the development on novel asthma therapies.
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CHAPTER 1 
INTRODUCTION
1.1 Asthma
1.1.1 Epidemiology
Asthma is the commonest chronic disease to affect both adults and children in the 
developed world^ and it is estimated that in the United Kingdom alone, there are more 
than 3 million people with the disease/ The clinical syndrome of asthma does not 
readily lend itself to a specific definition because of overlap with smoking related 
lung disorders which may also cause airflow obstruction and increased bronchial 
hyperresponsiveness. In 1986 however, the board of directors of the American 
Thoracic Society ratified a definition of asthma as “a clinical syndrome characterised 
by increased responsiveness of the tracheo-bronchial tree to a variety of stimuli. The 
major symptoms of asthma are paroxysms of dyspnoea, wheezing and cough, which 
may vary from mild and almost undetectable to severe and unremitting (status 
asthmaticus). The primary physiological manifestation of this hyperresponsiveness is 
variable airways obstruction, which can take the form of spontaneous fluctuations in 
the severity of obstruction, following bronchodilators or corticosteroids, or increased 
obstruction caused by drugs or other stimuli”.^
Despite considerable improvements in our understanding and management of asthma 
over the last two decades, studies from around the world would suggest that the 
prevalence of this illness continues to rise at an alarming rate."^  Asthma is responsible 
for considerable morbidity and mortality within the community, much of which is 
thought to be preventable.^ It is estimated that in the United Kingdom almost one in 
three patients suffer 3 or more exacerbations of asthma per year leading to absences 
from school or work which cost the country an estimated £400 million pounds per 
annum.^ During 1993 acute exacerbations of asthma accounted for more than 100
000 acute admissions to hospital in Scotland and England/ The British Thoracic 
Association confidential inquiry into asthma deaths in the 1980’s suggested that 
severe exacerbations of asthma accounted for more than 1500 deaths per annum in 
the United Kingdom and that avoidable factors were present in more than 80% of 
these deaths/ A recent Scottish confidential inquiry into asthma deaths investigated 
95 deaths between January 1994 and December 1996. This study found a significant 
fall in the calculated “deaths assessed as due to asthma” and detected significant 
improvements in overall asthma management when compared with the British 
Thoracic Association study of the 1980’s.^
The improvements in asthma mortality which have been observed reflect an increased 
understanding of the pathogenesis of this disease and with this improvements in the 
emphasis of asthma therapy and its delivery. Despite these improvements severe 
exacerbations of asthma remain a common reason for admission to hospital and are 
still associated with avoidable deaths.
1.1.2 Pathology
Early theories relating to the pathophysiology of asthma suggested that it was intrinsic 
abnormalities of autonomic neural innervation of the bronchial tree in patients with 
asthma, which resulted in variable airway obstruction and increased bronchial 
hyperresponsiveness. However within the last two decades it has emerged through 
intensive research that asthma is an inflammatory condition largely confined to 
airways, particularly the bronchi and smaller bronchioles.^ Early evidence for this 
hypothesis came from pathological studies of patients dying in ‘status asthmaticus’. 
The airway lumens of patients with asthma contained odema fluid, cellular debris and
inflammatory cells which had coalesced to form mucus plugs. These plugs found 
throughout the bronchial tree caused a reduction in airway calibre which contributed 
to the airflow obstruction observed in patients with asthma.^ Microscopy of 
pathological specimens confirmed the presence of increased smooth muscle bulk, 
glandular hyperplasia, separation of the superficial columnar cells from basal cells, 
odema of the airway walls and thickening of the basement membrane.^’^  ^ In addition 
to these striking structural changes, the airway walls themselves contained an intense 
inflammatory cell infiltrate. This cellular infiltrate included eosinophils which were 
found in large numbers both within the bronchial wall and migrating through it into 
the airway lumen. ^  Degranulated mast cells were also found in abundance within the 
airway wall and lumen. Recent intense interest has focused on the role of 
lymphocytes in the pathogenesis of asthma. This interest has been provoked by 
observations from biopsy studies in patients with asthma which have suggested that 
lymphocytes are found in the airway walls in even higher numbers than eosinophils, 
once thought to be the major effector cells of the asthmatic inflammatory response. 
Further classification of these lymphocytes has confirmed an abundance of T-helper 
cells within the airway walls with specific activation of the Th2 subgroup.
Recent biopsy studies from asymptomatic,^^ mild,^ "^  moderate and severeasthmatics 
have shown similar histological changes to those observed in patients dying from 
acute asthma. The only difference between these groups appears to be in the degree 
of histological change.^ This would suggest that inflammation is the main 
abnormality in patients with asthma. Studies examining biopsy samples from patients 
with extrinsic and intrinsic asthma have also shown little in the way of histological 
difference between these so called sub-groups.^
The pathological studies described above, in patients with asthma of varying severity, 
have confirmed that inflammation within the airway wall has a fundamental role to 
play in the pathophysiology of asthma. The association between inflammation and 
the development of airflow obstruction and more importantly bronchial 
hyperresponsiveness is further considered in the next section on the pathogenesis of 
asthma.
1.1.3 Pathogenesis
Many attempts have been made to classify patients with asthma into subgroups based 
on aetiology. These subgroups include extrinsic, intrinsic, occupational, exercise and 
aspirin induced asthma. While aetiologically a rather heterogenous group of 
conditions it has become increasingly apparent that they share common physiological, 
pathological and immunological mechanisms. Atopic asthma, the commonest form 
of extrinsic asthma with a readily identifiable aeroallergen, typically develops in 
childhood and early adulthood.^ It is the investigation of this form of asthma which 
provides the basis for much of our understanding of the pathogenesis of asthma today.
1.1.3.1 Cellular response
Inhalation of a specific aeroallergen in a sensitised individual, results in cross linking 
of IgE molecules bound to high-affinity receptors on mast cells. This process results 
in degranulation of mast cells and the release of a variety of preformed mediators into 
the airways. These mediators include histamine, prostaglandins, thromboxanes, 
leukotrienes and cytokines.^ These mediators have a wide range of functions but 
effectively trigger a cellular and molecular cascade which results in airway 
inflammation. Within 15-20 minutes of mast cell degranulation vascular leakage and
smooth muscle constriction are observed, a process which reverses spontaneously 
within hours and constitutes the early asthmatic response. In many patients a 
second phase of bronchoconstriction occurs and is characterised by the recruitment of 
eosinophils, lymphocytes and macrophages to the inflammatory response. This 
occurs between 6 and 12 hours after the initial challenge and may recur on subsequent 
days. This is termed the late asthmatic response and is associated with further 
bronchoconstriction and the development of increased airway responsiveness which is 
so typical in patients with asthma.
Pathological studies have already confirmed that a variety of cells are involved in the 
development and maintenance of the asthmatic inflammatory response. Degranulation 
of mast cells seem to provide the initial stimulus to the development of this response. 
Other cell types involved include eosinophils, once thought to be airway protective 
because of a capacity to degrade proinflammatory mediators such as histamine^ They 
are now recognised as one of the major effector cells of the inflammatory response in 
asthma. They are found in considerable numbers in the airways of asthmatic patients 
both spontaneously^^ and in response to allergen challenge.They secrete a number 
of toxic substances including eosinophil peroxidase, major basic and eosinophil 
cationic proteins which cause considerable disruption to airway epithelium.
Treatment of atopic asthmatics with regular inhaled corticosteroids results in a 
significant reduction in airway eosinophil counts, improved control of asthma 
symptoms and a reduction in airway hyperresponsiveness.^^
Macrophages, the commonest cell type found in airways, have low affinity IgE 
receptors on them suggesting a role in allergic mediated asthma. Recovery of mast
cells from bronchoalveolar lavage fluid following allergen challenge show increased 
production of eicosanoid mediators and GM-CSF which may prolong eosinophil 
survival/^ Macrophages may also have a regulatory role in the inflammatory cascade 
altering the activity of lymphocytes and controlling recruitment of eosinophils and 
neutrophils to the airway inflammatory response/"^
In recent years increasing interest has focused on the role of lymphocytes in the 
asthmatic inflammatory response. Activated lymphocytes have been found in large 
numbers in the airway mucosa of patients with asthma^ ^ and are found in direct 
proportion to the number of eosinophils.^^ The production of specific IgE by B- 
lymphocytes is a well recognised feature of atopic asthma. The role of T- 
lymphocytes is less well understood. It is thought they may act as immune 
modulators in the asthmatic inflammatory response. T-helper lymphocytes have been 
divided into Thl and Th2 subgroups. These groups appear mutually inhibitory^ '^^  ^ It 
is thought that Th2 lymphocytes on the basis of their cytokine profile (secretion of IL- 
3, IL-4, IL-5 and GM-CSF) promote the inflammatory response in asthma by 
stimulating IgE synthesis and potentiating mast cell and eosinophil function.^^ Thl 
lymphocytes appear to oppose these actions. The role of neutrophils and platelets in 
the production and propagation of the acute inflammatory response and subsequent 
development of bronchial hyperresponsiveness remains controversial and poorly 
understood in patients with asthma.^
1.1.3.2 Inflammatory mediators
It is becoming increasingly clear that the development and maintenance of the 
asthmatic inflammatory response involves a complex interaction between a number of
different cell types and the mediators they secrete. These mediators have a number of 
functions. They are thought to act directly on airway smooth muscle causing 
bronchoconstriction, increase microvascular leakage from airway capilliaries, 
enhance mucus secretion from mucosal glandular cells, promote chemotaxis and 
activate other inflammatory cells. ^  It is beyond the scope of this introduction to 
discuss all of the inflammatory mediators which have been implicated in the 
asthmatic inflammatory response. The role of several of the more important 
mediators are discussed below.
Histamine is released following degranulation of mast cells and basophils. Levels of 
histamine have been found to be elevated in BAL fluid obtained from asthmatic 
patients at rest and in response to allergen cha l lenge .H is tam ine  causes airway 
smooth muscle contraction,^^ potentiates microvascular leakage producing airway 
odema^ "^  and stimulates mucus secretion into the airway lumen.
The cysteinyl leukotrienes are formed from the arachidonic acid pathway by the 
action of the enzyme 5-lipoxygenase. They are potent inflammatory mediators 
causing cell chemotaxis, neural bronchoconstriction, microvascular leakage and 
mucus hypersecretion.^^ Cysteinyl leukotrienes are found in high levels in the BAL 
fluid and urine obtained following allergen challenge in patients with asthma. 
Recently developed cysteinyl-leukotriene receptor antagonists have been shown to 
attenuate both allergen,^^’^  ^exercise,and aspirin-induced asthma.'^^’'^  ^ Clinical 
studies with these antagonists in patients with mild to moderate asthma have shown 
significant improvements in asthma symptoms and lung function when compared to
p l a c e b o . These studies would suggest an important role for leukotrienes in 
propagating the asthmatic inflammatory response.
Prostaglandins produced by the enzyme cyclo-oxygenase are also found to be elevated 
in the BAL fluid obtained from asthmatic patients at rest and following allergen 
challenge. PGD2 and PGF2a are potent bronchoconstrictors'^^’'^  ^and potentiate 
airway hyperresponsiveness to histamine and methacholine."^  ^ Interestingly however 
cyclo-oxygenase inhibitors have little clinical effectiveness in asthma suggesting a 
limited role for these mediators in the propagation of the asthmatic inflammatory 
response.
Cytokines and chemokines are a group of more than 50 peptide mediators, secreted by 
inflammatory cells which seem to have an important role in cell signalling. These 
mediators appear to have both pro and anti-inflammatory activity. They are 
principally involved in the maintenance of chronic inflammation in patients with 
asthma. They include the Interleukins lL-8, Tumour necrosis factor-a. Granulocyte- 
macrophage colony-stimulating factor and the interferons. Their actions, which are 
diverse and not yet fully understood, include promotion of IgE production from B 
lymphocytes,^^ enhancement and suppression of antigen presentation via 
macrophages,^^’^  ^ increased cell chemotaxis and activation of inflammatory cells 
within the airways. Considerable research efforts continue to be made into 
detennining the exact role of cytokines and chemokines in the development and 
maintenance of the inflammatory response. It is clear however that they are an
extremely important group of inflammatory mediators and improved understanding of 
their actions may open the door to the development of novel anti asthma therapies.
1.1.3.3 Neural innervation
Neural innervation of the airways is complex and still poorly understood in relation to 
the development and maintenance of asthmatic symptoms. Airway smooth muscle 
derives its innervation from several sources including vagal afferents, post ganglionic 
non-cholinergic vagal efferents and a non-adrenergic non-cholinergic supply. 
Autonomic innervation of the lungs has influences on smooth muscle tone, vascular 
permeability, mucus secretion and blood flow. It has been postulated that abnormal 
neural innervation of the airways contributes to the bronchoconstriction seen in 
asthma. It is thought however that this represents a secondary effect of the 
inflammatory process rather than a primary defect within the autonomic nervous 
system as was previously thought. Several mechanisms resulting in neural 
bronchoconstriction have been proposed including stimulation of vagal afferent C- 
fibres within the airways leading to cough and bronchoconstriction,^*^ increased 
acetylcholine release from post ganglionic nerve endings^^ and intrinsic abnormalities 
of muscarinic receptors on cholinergic nerves. Others have hypothesised that the non- 
adrenergic non-cholinergic innervation may contain intrinsic defects in patients with 
asthma which result in the loss of a natural hronchodilator pathway.^^ That neural 
mechanisms have a role in the bronchoconstriction seen in asthma is generally agreed, 
the mechanisms however remain poorly understood.
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1.1.3.4 Summary
The last two decades have seen significant advances in the understanding of the 
pathogenesis of asthma. The development of flexible fibre optic bronchoscopy 
allowing ready access to the lower airways for biopsy and bronchoalveolar lavage 
allied to advances in molecular biological techniques and the use of induced sputum 
have significantly increased our knowledge of the pathogenesis of asthma. Early 
beliefs that asthma occurred as a consequence of imbalances between inhibitory and 
excitatory autonomic nervous innervation of airways have now been shown to be 
somewhat simplistic. Asthma is an inflammatory condition affecting the airways of 
sensitised individuals. Triggers of asthma produce a complex inflammatory cascade 
within the airways involving a wide range of inflammatory cells and the mediators 
they secrete. It is the inflammatory process described above which produces the 
variable airflow obstruction and increased bronchial hyperresponsiveness that is so 
typical of asthma. The clinical symptoms that this inflammation process produces 
may vary from mild and almost unnoticeable in some patients to severe and 
occasionally fatal in others.
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1.2 Acute Severe and Life Threatening Asthma
1.2.1 Introduction
While evidence now exists which suggests that mortality from asthma is declining^ 
the number of admissions to hospital with acute severe and life threatening 
exacerbations of asthma appears unchanged. Studies have suggested that avoidable 
factors can be detected in more than 75% of these admissions. Patients themselves 
often underestimate the severity and duration of severe attacks and may delay seeking 
medical help. Later questioning of patients who survive their hospital admission may 
reveal asthma symptoms which have been troublesome for several days and in some 
cases several w eeks .O ther  factors associated with the development of life 
threatening exacerbations of asthma include additional psychosocial problems, 
previous hospital admission, previous severe attacks, being an adolescent or young 
adult, high hronchodilator demand or oral corticosteroid use, intermittent nebuliser 
use and patients showing marked diurnal variation on peak flow recording.
1.2.2 Presentation and assessment
Patients usually recognise the symptoms of an acute exacerbation which may include 
increasing breathlessness, wheeze, cough, chest tightness, reduced effort capacity, 
troublesome nocturnal symptoms and failure to respond to their usual medication.^ ^ 
They are however less able to determine the severity of their exacerbation, possibly 
due to tolerance of chronic symptoms or blunted perception to developing airflow 
obstruction. It is well recognised that both hospital doctors^ "^  and family 
practitioners^^ faced with a patient suffering from an acute exacerbation of asthma 
will also underestimate the severity of the exacerbation and as a consequence will 
under prescribe anti-inflammatory and rescue hronchodilator medication,
1 2
occasionally with fatal consequences/ Proper assessment of the severity of an acute 
exacerbation requires objective measurements to be made. With this in mind the 
British Thoracic Society in conjunction with the British Paediatric Association, 
National Asthma Campaign and others produced guidelines for the recognition and 
assessment of patients with acute severe and life threatening exacerbations of 
asthma.
It is recommended that objective measurements of respiratory rate, heart rate, peak 
expiratory flow rate (PEFR), blood pressure, gas exchange and general observations 
about the patient are made. An acute severe exacerbation should be suspected when 
the patient is unable to complete sentences, has a PEFR less than 50% of predicted or 
best, a respiratory rate > than 25 breaths/minute and a heart rate > than 110 
beats/minute. Life threatening features of acute asthma include PEFR less than 33% 
of predicted or best; silent chest, cyanosis or feeble respiratory effort; bradycardia or 
hypotension; exhaustion, confusion or coma.^^
The majority of patients admitted to hospital with acute severe and life threatening 
asthma will be hypoxaemic and approximately one third will have a Pa0 2  of less than 
8.0 kPa when breathing room air.^ ’^^  ^ A minority, approximately 10% of patients will 
have severe hypoxaemia with a Pa02 of less than 6.0 kPa.^  ^ Patients who are 
admitted to hospital usually have a low PaC0 2  as a consequence of hyperventilation. 
In those patients with a normal PaC02 the possibility of a more severe exacerbation is 
raised and the potential to develop hypoventilation should be documented. 
Approximately 5-10% of patients present with hypercapnia. These patients have 
already developed hypoventilation as a consequence of severe airflow obstruction and 
are at greatest risk of dying.Patients who have any life threatening feature and
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those with an oxygen saturation (Sa02%) of less than 92% should therefore have their 
blood gases measured and documented.
1.2,3 Management
The management of acute severe and life threatening exacerbations of asthma are 
contained within guidelines issued by the British Thoracic Society and other 
interested parties. Patients should immediately receive high inspired oxygen 
tensions with an Fi02 in excess of 60% in an attempt to raise Pa02 above 8.0 kPa and 
ideally to between 10 and 14 kPa. It is rare for patients with asthma to develop 
hypoventilation as a consequence of oxygen therapy.^^ Nebulised bronchodilators 
should be administered and nebulisers should be driven by oxygen with a flow rate of 
7 litres per minute. Salbutamol or terbutaline are the most commonly used 
bronchodilators. Nebulised ipratropium bromide can also be administered, although 
some physicians delay its use for 15-30 minutes and only give it to patients not 
improving with their initial treatment. Oral corticosteroids or intravenous 
hydrocortisone, in those patients unable to tolerate oral drugs, should be given 
immediately on admission.
The objective measurements made during the initial assessment should be repeated 
within 15-30 minutes of admission to hospital. Patients not improving or who have 
evidence of deterioration should receive further nebulised p2"agonists at 15 minute 
intervals and ipratropium bromide if they have not already done so. Intravenous 
infusions of aminophylline, salbutamol or terbutaline should be commenced with 
bolus injections where appropriate. Once patients have stabilised transfer to a 
suitable medical ward should be arranged and patients continued on oxygen therapy,
14
oral or intravenous corticosteroids and 4 hourly nebulised bronchodilators as well as 
any intravenous bronchodilators that have been commenced.
Patients who continue to deteriorate despite the above measures should be considered 
for admission to the intensive care unit.^  ^ Current indications for referral to such a 
unit include persisting hypoxia (Pa02 < 8.0 kPa) despite an inspired Fi02 > 60%, 
hypercapnia (PaC02 > 6 kPa), exhaustion, feeble respiration, confusion, drowsiness, 
coma or following a respiratory arrest.
It is recommended that patients are discharged from hospital following resolution of 
nocturnal symptoms, when PEFR has risen to greater than 75% of predicted or best 
and twice daily PEFR shows less than 25% diurnal variation. Patients should be 
established on their discharge medication for 24-48 hours prior to discharge and the 
dose of inhaled corticosteroids is usually higher than admission. Inhaler technique 
should have been assessed and arrangements should be in hand for asthma clinic 
review within one month of discharge.
1.2.4 Summary
Despite an apparent fall in the mortality of acute asthma in recent years severe and 
life threatening exacerbations remain a common reason for admission to hospital. A 
significant number of such patients will be hypoxaemic and as part of their routine in- 
hospital management will receive high inspired oxygen tensions to inhale as well as 
nebulised and occasionally intravenous bronchodilators.
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1.3 The effect of acute alterations in oxygen and carbon dioxide tension on 
airway tone in isolated bronchial rings
1.3.1 Effects on resting tone
Hypoxia and hypercapnia are associated with a variety of both acute and chronic 
cardio-respiratory illnesses in man. As part of the management of these illnesses 
patients often have elevated inspired oxygen tensions administered in an attempt to 
correct hypoxia. It is not surprising therefore that researchers have, for some time, 
been interested in the effects of both acute and chronic alterations in oxygen (PaOi) 
and carbon dioxide (PaCOz) tension on smooth muscle resting tone, and on 
subsequent contraction of that smooth muscle following both electrical and 
pharmacological challenge. The effect of acute alterations in oxygen and carbon 
dioxide tension on smooth muscle responses from a variety of organs including lung, 
heart, vasculature, kidney and uterus have previously been examined and it is 
apparent that the responses between these organs vary quite considerably.
Stephens et a f  ^ have previously demonstrated that in canine isolated bronchial rings, 
obtained from the first intrapulomonary division of the left lower lobe of mongrel 
dogs, suspended in vertical organ baths a reduction in ambient PaOz from 630 mm Hg 
to 60 mm Hg whilst maintaining a constant pH and PaCOz is associated with a small 
but significant (p<0.05) rise in resting tone in the bronchial rings of approximately 
5% when compared to a control group. In isolated pulmonary arterial rings from 
several species including rats, sheep and pigs a similar reduction in ambient oxygen 
tension also causes a significant increase in resting tension. '^  ^ This increase causes 
pulmonary arterial constriction and is thought to represent a reflex response within 
the pulmonary vasculature to hypoxia which improves ventilation perfusion matching.
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This effect should however be contrasted with skeletal, gastrointestinal and cerebral 
vascular rings where a reduction in PaOi below 40 mm Hg causes a marked reduction 
in resting tension^ "^  and results in vasodilation, Stephens et al have also examined the 
effect of acute alterations in carbon dioxide levels on canine isolated bronchial 
rings/^ They observed a small but significant rise (p<0.05) in resting tension 
following a reduction in PaC02 from 42 mm Hg to 25 mm Hg while Pa02 was 
maintained at 630 mm Hg and pH at 7.41. Conversely a rise in PaC02 from 42 mm 
Hg to 76 mm Hg while maintaining a pH of 7.41 and Pa02 of 630 mm Hg was 
associated with a small but significant (p<0.05) fall in resting tension. It would 
appear therefore that acute alterations in both oxygen and carbon dioxide tensions 
alone have significant, although variable, effects on smooth muscle tone in isolated 
rings from different tissues and species.
1.3.2 Effects on electrical stimulation
Studies in-vitro have examined the effect of supramaximal electrical stimulation, in 
different oxygen tensions, on the development of maximum active tetanic tension, 
maximum rate at which tension develops and the time to development of maximum 
tension in smooth muscle from canine isolated tracheal rings.^ '^^  ^ Stephens et al have 
suggested that in tracheal rings maintained at a constant length (L^ax) the maximum 
active tetanic tension (AP^ax) produced following supramaximal electrical stimulation 
is significantly reduced by hypoxia (Pa02 60 mm Hg) when compared to control 
tracheal rings with an ambient oxygen tension of 630 mm Hg. Hypoxia also resulted 
in a significant reduction in the rate of development of active tetanic tension 
(dP/d^ )niax and an increase in the length of time to the development of maximum 
tension (rApmax)- The authors have postulated that hypoxia impairs mitochondrial
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function reducing intracellular energy release and reducing the ability of smooth 
muscle to constrict in response to electrical stimulation. This effect does not appear 
to relate to the development of intracellular acidosis or impaired depolarisation of 
potassium channels.^^’^ ^
1.3.3 Effect on pharmacological challenge
Recent studies carried out in our own laboratories have examined the effect of acute 
alterations in oxygen tension on responses evoked by a variety of bronchoconstrictor 
and bronchodilator stimuli in isolated bovine and rat isolated bronchial r i n g s . T h e  
acute effects of three different oxygen tensions; 95% 0^ (hyperoxia), 20% O2 
(normoxia) and 4% O2 (hypoxia) on methacholine induced tone in bovine isolated 
bronchial rings were examined. Cumulative concentration-response curves to 
methacholine (10'^ - 3 x lO '^M) were constructed in each of the oxygen tensions. 
Results for subsequent statistical analysis were expressed as a percentage of the 
maximum response in 95% O2. The constrictor response to methacholine was 
significantly greater (p<0.001) in the 20% and 4% O2 when compared to 95% O2. 
There was no significant difference between 2% and 4% O2. When a single 
concentration of methacholine (3 x 10'  ^M) was used to constrict the bovine isolated 
bronchial rings similar results were found. The resultant contraction was greater in 
20% and 4% O2 when compared to 95% O2 (p<0.001) but again no significant 
difference in contractions was found between oxygen tensions of 20% and 4%.
Similar studies^  ^have also been performed looking at the effect of acute changes in 
oxygen tension (95%, 20%, 4%) on concentration-response curves (10'^° - 3 x 10'  ^M) 
to endothelin-1 in bovine isolated bronchial rings. Hypoxia (O2 4%) significantly 
(p<0.001) potentiated and hyperoxia (O2 95%) significantly attenuated (p<0.001) the
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contractions evoked by endothelin-1 when compared to 20% O2. It is interesting to 
note that the effect of hypoxia on endothelin-1 mediated contractions was completely 
abolished by the addition of indomethacin, a cycloxygenase inhibitor.^^
Our laboratory has also examined the effect of acute alterations in oxygen tension 
(95%, 20%, 4%) on methacholine-induced contractions in rat isolated bronchial 
rings/^ The results from this work differs quite markedly from what we have 
previously described in bovine isolated bronchial rings. In a similar series of studies 
cumulative concentration-response curves were constructed to methacholine (10'^ - 3 
X 10 "^ M) for rings of rat bronchi suspended in vertical organ baths. Changing the 
oxygen tension from 95% to 20% had no effect on responses evoked by methacholine. 
However when the oxygen tension was further reduced to 4% the constrictor response 
to methacholine was significantly attenuated (p<0.001). This observation was also 
found in rat isolated bronchial rings from chronically hypoxic rats which had been 
reared in a hypoxic chamber for 14 days.^ ® These findings differ significantly from 
the observations we have made in bovine isolated bronchial rings but are in keeping 
with results reported by other groups.^^’^ ^
Vannier et al have also studied the effect of acute alterations in oxygen tension on 
KCl and carbachol induced constriction in third and fourth order porcine isolated 
bronchial rings.T heir group has reported that a reduction in oxygen tension from 
95% to 0% caused a highly significant shift of the concentration-response curves for 
both carbachol (p<0.005) and KCl (p<0.0001) to the right indicating a reduction in 
tone generated during hypoxic conditions. On returning to hyperoxic conditions (O2 
95%) tone was restored to initial resting levels. In carbachol constricted rings this
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observation was not significantly altered by removal of bronchial epithelium or the 
addition of indomethacin (a cyclooxygenase inhibitor), methylene blue (a soluble 
guanylate cyclase inhibitor) or propranolol (a B-adrenoceptor antagonist). In a second 
series of experiments, the effect of a stepwise reduction in ambient oxygen tension 
(95%, 50%, 28%, 10% and 3%) on carbachol and KCl generated tone in porcine 
isolated bronchial rings was examined. On this occasion bronchial rings both with 
and without an intact epithelium were studied. They found that the degree of hypoxic 
relaxation of porcine rings pre-constricted with carbachol and KCl (O2 95%) was 
proportional to the reduction in oxygen tension and that this relationship was linear. 
The presence or absence of an intact epithelium did not influence this observation 
suggesting that bronchial epithelium does not secrete a relaxant factor as had 
previously been suggested. In a later series of studies exploring the possible 
mechanisms of hypoxic relaxation^^ following pharmacological challenge Vannier et 
al have examined the effect that BAY K 8644 (a L-type Ca^  ^channel agonist) has on 
hypoxic relaxation of porcine isolated bronchial rings pre-constricted with carbachol 
and KCl. BAY K 8644 completely abolished hypoxic relaxation in porcine rings pre- 
constricted with KCl (40 mM) at all oxygen tensions (5%, 28%, 10% and 3%) but had 
no effect on porcine rings constricted with the cholinergic agonist carbachol. This 
would suggest that a possible mechanism to explain the observation of hypoxic 
relaxation may be inhibition of calcium entry into cells.
Gao and Vanhoutte^^ have also considered the importance of an intact bronchial 
epithelium on hypoxic relaxation of canine isolated bronchial rings pre-constricted 
with carbachol (3 x 10'  ^M) In their studies the magnitude of relaxation of canine 
isolated bronchial segments was dependent on both the level of hypoxia used (600
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mm Hg, 140 mm Hg, 80 mm Hg and 40 mm Hg) in the organ bath and also on the 
presence of an intact bronchial epithelium. This clearly differs from the findings of 
Vannier et al.^  ^ The preparations in which the epithelium had been removed showed 
no significant relaxation at any oxygen tension when compared to controls. They 
have suggested that bronchial epithelium in response to hypoxia may release an 
unknown relaxing factor to explain the observation of hypoxic relaxation following 
pharmacological challenge. In keeping however with the results of Vannier et al they 
also found that indomethacin, methylene blue, propranolol and trodotoxin (a sodium 
channel blocker) did not alter the magnitude of hypoxic relaxation in the epithelium 
intact preparations.
We have up until now considered only the effect of acute alterations in oxygen 
tension on constrictor stimuli in a variety of tissues in-vitro. Our laboratory has 
recently undertaken studies to examine the effect of hypoxia, normoxia and hyperoxia 
on the ability of bronchodilator drugs to reverse airway tone in bovine isolated 
bronchial rings pre-constricted with methacholine (3 x 10 '" The drugs used:
salbutamol, atrial natriuretic peptide and isosorbide dinitrate were selected on the 
basis of their postulated mechanisms of action. Salbutamol is a Bi-adrenoceptor 
agonist which stimulates intracellular adenylate cyclase causing a rise in cyclic 
adenosine monophosphate (cAMP) as well as opening channels. Atrial natriuretic 
peptide (ANP) stimulates particulate guanylate cyclase causing a rise in cyclic 
guanosine monophosphate (cGMP). Isosorbide dinitrate also causes a rise in cGMP 
but by stimulating soluble guanylate cyclase. Each of these actions results in smooth 
muscle relaxation. Cumulative concentration-response curves were constructed for 
each of these dilators: salbutamol (10'^ - 3 x 10’^  M), atrial natriuretic peptide (10'^ -
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10'  ^M) and isosorbide dinitrate (10’^  - 3 x 10'  ^M) in oxygen tensions of 95%, 20% 
and 4% for bovine isolated bronchial rings pre-constricted with methacholine (3x10" 
 ^M). The ability of salbutamol to reverse tone in bovine bronchial rings constricted 
with methacholine was significantly reduced (p<0.001) by an oxygen tension of 4% 
when compared to 20%. Conversely atrial natriuretic peptide (p<0.05) and isosorbide 
dinitrate (p<0.001) caused significantly greater reversal of tone at an oxygen tension 
of 4% when compared to an oxygen tension of 20%. There was no significant 
difference for salbuatmol or atrial natriuretic peptide when oxygen tensions of 95% 
and 20% were compared. Isosorbide dinitrate caused greater relaxation (p<0.01) at 
an oxygen tension of 20% when compared to 95%.
1.3.4 Summary
It is apparent that acute alterations in oxygen tension have quite profound effects on 
the ability of smooth muscle to contract, alone, following electrical stimulation and 
pharmacological challenge. Smooth muscle responses however are unpredictable and 
vary significantly depending on the species, type of tissue used and the ambient 
oxygen tension within the organ bath. These observations may however have 
important implications for patients with acute exacerbations of asthma.
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1.4 The effect of acute alterations in oxygen and carbon dioxide tension on 
airway tone in animals in-vivo
1.4.1 Effects on resting tone
The effect of acute alterations in ambient oxygen and carbon dioxide tensions on 
airway tone in animals has been of interest since the late nineteenth century, but to 
date no consensus about their effect has been reached by scientists. The earliest 
studies by Roy and Brown in 1885^^and Dixon and Brodie in 1903^ "^  suggested that 
asphyxia, hypoxia and hypercapnia caused tracheal and bronchial constriction and 
that these effects were dependent on intact vagal innervation.
These observations were later revisited by Nadel and Widdicombe who in 1962 again 
examined the effect of changes in oxygen tension on the lung mechanics of 
anaesthetised dogs.^  ^ They showed that in dogs ventilated at a constant rate and tidal 
volume, lowering the inspired oxygen tension from 90 mm Hg to 37 mm Hg (Fi02 
10%) resulted in a significant increase in total lung resistance (p<0.01) and reduction 
total tracheal volume (p<0.01). These changes were not associated with any 
significant change in pulmonary compliance. In a separate series of studies Nadel 
and Widdicombe have also considered the effect of sequentially ventilating the dogs 
with different oxygen tensions (Fi02 21%, 15% and 10%) to form a dose response 
curve. From this study they were able to show that the increase in total lung 
resistance observed with hypoxia was linear and was inversely proportional to the 
inspired oxygen tension administered to the dogs.^^
In a similar series of studies the effect of hypercapnia, inhalation of an FiC02 80%, 
was exam ined.Raising the mean PaC02 from 32 mm Hg to 66 mm Hg resulted in a
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significant increase in total lung resistance and fall in tracheal volume but no change 
in pulmonary compliance. This was similar to the pattern seen with hypoxia but of a 
lesser magnitude. It was also shown at this time that the degree of 
bronchoconstriction was proportional to the level of hypercapnia and that the 
relationship was linear.
In a further series of studies Nadel and Widdicombe observed that the changes in 
pulmonary dynamics seen with hypoxia were abolished by vagosympathetic cooling, 
which resulted in a physiological denervation, and tying off the glossopharyngeal 
nerves. They suggested that bronchoconconstriction was initiated by hypoxic 
stimulation of carotid chemoreceptors which subsequently stimulated motor efferents 
in the vagus nerve causing an increase in smooth muscle tone. The 
bronchoconstriction seen with hypercapnia was also abolished by cooling the 
vagosympathetic nerves but unaffected by tying off the glossopharyngeal nerve.
Nadel and Widdicombe suggested that hypercapnie constriction was mediated via the 
vagosympathetic chain. However this cannot be the entire explanation as isolated 
bronchial rings deprived of their neural innervation and circulating humoral factors 
also display changes in smooth muscle tone with different oxygen and carbon dioxide 
tensions.
The findings of Nadel and Widdicombe are in agreement with those of Green and 
Widdicombe^^ and Loofbourrow et af^ who also demonstrated an increase in total 
lung resistance, reduction in tracheal volume and reduction in the airway anatomical 
dead space when ventilating dogs with an inspired oxygen tension of 10%. They were 
also unable to demonstrate any significant difference in pulmonary compliance. In
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addition they also examined the effect of raising the inspired oxygen tension to 100% 
and showed a small but significant bronchodilation, observing a reduction in total 
lung resistance and a rise in both tracheal volume and anatomical dead space. This 
however was not the findings of Vidruk and Sorkness^* who were unable to 
demonstrate any change in the airway tone of dogs ventilated with 10% oxygen. They 
did however find that approximately 50% of the dogs in their study breathing an 
inspired oxygen tension of 10% showed an increase in total lung resistance in keeping 
with bronchoconstriction. In the late eighties and early nineties, Ahmed and 
Marchette examined the effect of inhaling 13% oxygen on specific lung resistance 
(SRL) in conscious sheep. Eleven conscious sheep inhaled 13% oxygen balanced 
with nitrogen or an air sham for 30 minutes. Measurements of airway resistance 
made at baseline were then repeated. There was no significant difference in specific 
lung resistance between the groups suggesting that in conscious sheep hypoxia does 
not affect resting airway tone.^^
To add to the confusion Wetzel et al °^ examined the effect of inhaling 7% oxygen on 
airway calibre in anaesthetised minipigs. In this study minipigs were anaesthetised 
and paralysed before having a tracheostomy fashioned. They were then ventilated 
sequentially with both hypoxic and normoxic gas mixtures for 15 minutes each, with 
a period of recovery in between. Airway calibre was assessed using high resolution 
computed tomography scanning. They confirmed hypoxia by measuring arterial 
blood gases. In 70 out of 76 airways examined hypoxia resulted in an increase in 
airway calibre which returned to normal during normoxia. They calculated that this 
represented a mean fall in airway resistance of 45%. These observations are clearly 
different from those already reported in earlier studies.
25
1.4.2 Summary
It is apparent once again that acute alterations in ambient oxygen and carbon dioxide 
levels have significant effects on airway tone in-vivo in animals. There is however 
considerable variation in the results found by different groups. There appear to be a 
number of confounding variables between the studies which include differences in the 
inspired oxygen tension used, differences in the species of animal studied and the 
presence or absence of drugs used for anaesthesia and paralysis in the animal models. 
It is therefore difficult to reach firm conclusions about the effect of acute alterations 
in oxygen and carbon dioxide levels in-vivo in animals,
1.4.3 Effects on bronchial reactivity in-vivo in animals.
A number of studies in animals have considered the effect of acute alterations in 
ambient airway oxygen tension on non-specific bronchial reactivity. Vidruk and 
Sorkness^^ examined the effect of both hyperoxia (Pa02 344 mm Hg) and hypoxia 
(Pa02 45 mm Hg) on histamine induced constriction of tracheal segments in 22 
anaesthetised and paralysed mongrel dogs. They found that an inspired oxygen 
tension of 100% significantly attenuated (p<0.005) histamine induced tracheal 
constriction and that an inspired oxygen tension of 12% significantly potentiated 
tracheal constriction (p<0.01). In subsequent studies following combined cervical 
vagotomy and bilateral transection of the superior laryngeal nerve in anaesthetised 
and paralysed mongrel dogs the changes in airway reactivity seen with alterations in 
inspired oxygen tension were abolished. In a similar study using awake sheep 
Denjean et al^  ^ showed a significant increase in bronchial reactivity to metahcholine 
when sheep inhaled a hypoxic gas mixture (Fi0 2  15%) compared to a control group
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breathing an air sham (Fi02 21%). Following peripheral surgical chemodervation the 
effect of hypoxia on methacholine induced bronchial reactivity was lost.^  ^ Denjean et 
al and Vidruk and Sorkness have concluded from their studies that the changes in 
bronchomotor tone following inhalation of methacholine and histamine at different 
oxygen tensions are due to reflex interactions between sensory c-fibres and carotid 
chemoreceptors rather than a direct effect of histamine or methacholine and oxygen 
on airway smooth muscle tone. Interestingly these observations are at odds with the 
in-vitro findings where isolated bronchial rings deprived of their neural innervation 
continue to display changes in smooth muscle tone following pharmacological 
challenge. It is perhaps worth noting that a variety of agents were used in these 
animals to induce and maintain anaesthesia and paralysis including ketamine, 
chloralose, urethane and gallamine triethiodide. These drugs may themselves have 
direct effects on smooth muscle tone and neuromuscular transmission which may 
have influenced their results.
D’Brot and Ahmed have performed similar studies in conscious sheep which had not 
been paralysed. They have compared the effect of breathing a hypoxic (Fi0213%) 
and normoxic (Fi02 21%) gas mixture for 30 minutes on non-specific bronchial 
reactivity to both inhaled histamine and carbachol. In their first study they found that 
specific lung resistance (SRL) in sheep after inhaling histamine increased by 337% 
breathing air and 621% breathing a hypoxic gas mixture (p<0.01). Likewise 
carbachol induced bronchoconstriction was potentiated by hypoxia. Specific lung 
resistance increased by 342% breathing air and 646% breathing the hypoxic gas 
mixture (p<0.01). In later studies they were able to demonstrate that infusion of 
cromolyn sodium,which acts to stabilise mast cells and reduce histamine release.
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abolished the additional bronchoconstriction produced by hypoxia. In a similar study 
pretreatment of the sheep with FPL 57231 a novel leukotriene receptor antagonist was 
also capable of abolishing the effect of hypoxia on histamine induced 
bronchoconstriction.^^ Potentiation of bronchoconstriction by hypoxia was 
unaffected by pretreatment of sheep with oral indomethacin suggesting that this 
mechanism is not mediated via the cycloxygenase pathway. They suggested from 
these investigations that alveolar hypoxia may stimulate degranulation of mast cell 
and release of mediators which in turn increases non-specific bronchial reactivity.
1.4.4 Summary
In animals in-vivo hypoxia appears to potentiate and hyperoxia attenuate non-specific 
bronchial reactivity. The mechanism of these effects are less well understood, but 
both release of local inflammatory mediators and reflex bronchoconstriction 
following stimulation of carotid chemoreceptors have been suggested as possible 
causes. These observations may have relevance in the management of patients with 
acute exacerbations of asthma.
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1.5 The effect of acute alterations in inspired oxygen and carbon dioxide tension 
on airway tone in-vivo in man
1.5.1 Effects on resting airway tone
The development and maintenance of airway tone in man is complex. It depends on 
a number of variables which include circulating humoral factors, neurotransmitters 
released from nerve endings, substances released locally within the airways which 
may effect smooth muscle tone and the physical properties of inspired gases. The 
physical properties of the lungs and airways themselves will also influence airway 
tone. These properties include the thickness of the airway wall, forces applied by 
surrounding structures which oppose smooth muscle shortening and the length- 
tension relationships of the smooth muscle itself. This complex relationship makes 
airway calibre difficult to measure in-vivo and despite considerable research efforts 
over the years the effect of acute alterations in inspired oxygen tension on airway tone 
in man remain controversial. This controversy exists because of the wide variation in 
protocols that have been used to examine this hypothesis. These include different 
techniques used to induce hypoxia, variable control of hypocapnia, variable levels of 
inspired oxygen tension administered to subjects and most importantly different 
techniques used to measure airway calibre.
The earliest studies examining the effect of acute hypoxia on airway tone were 
stimulated by the prospect of early flight and the effect that hypoxia might have on 
both pilots and passengers. From studies performed in the 1950's by Milic-Emili and 
Petit^  ^it was observed that acutely lowering the level of inspired oxygen from 50% to 
21% to 10% had no effect on airway resistance or dynamic compliance in the lungs of 
trained healthy volunteers. These observations were in keeping with those of
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Goldstein et who examined the effect of acute hypoxia on lung volumes and 
maximum expiratory flow volume curves in 15 normal subjects (9 male). In order to 
determine the effect of hypoxia on small airway function as well he compared the 
effect of four different gases including air, nitrogen-hypoxia, helium-normoxia and 
helium-hypoxia. Using a rebreathing method hypoxia was induced and the hypoxic 
studies were commenced once an oxygen saturation of 75% had been reached. In all 
studies the end-tidal carbon dioxide levels were maintained at a constant level. In 
their study Goldstein et al, like Milic-Emili and Petit were also unable to show any 
significant change in static lung volumes or maximum expiratory flow volume curves 
when comparing hypoxic and normoxic study days in their subjects. In a study 
looking at ten mild asthmatic patients Denjean et al,^  ^using an inspired oxygen 
tension of 15% under isocapnic conditions, was also unable to demonstrate any 
change in dynamic pulmonary compliance or airway calibre in their subjects after 
they had inspired a hypoxic gas mixture for ten minutes.
These results differ however from the findings of Sterling^^ who has also examined 
the effect of acutely lowering the inspired oxygen tension, on pulmonaiy physiology 
in normal subjects, from 21% through 12% and 10%. Using whole body 
plethysmography in six normal subjects (3 smokers), who were familiar with the 
operation of a body box, he demonstrated that lowering the inspired oxygen tension 
from 21% to 12% and 10% over a period of twenty minutes caused a statistically 
significant fall in specific airway conductance (^Gaw) and rise in thoracic gas volume 
(Fig) in keeping with bronchoconstriction. This effect was abolished within minutes 
of the subjects starting to inspire room air instead of the hypoxic gas mixture. 
Sterling^^subsequently showed in a second series of studies that the
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bronchoconstrictor effect observed when normal subjects inspired a hypoxic gas 
mixture (Fi0 2 12% and 10%) was completely abolished by the inhalation of nebulised 
orciprenaline prior to the study but not by the administration of 1.2mg of intravenous 
atropine. He concluded from these observations that hypoxia must cause 
bronchoconstriction by a direct action on airway smooth muscle cells of the bronchi 
as orciprenaline is a smooth muscle relaxant. The failure of atropine to prevent 
hypoxic bronchoconstriction suggests that the effect is not mediated via vagal nerve 
fibres within the bronchial tree although it is acknowledged by the authors that 1.2mg 
of atropine may have been insufficient to completely abolish vagal input. The 
changes in airway resistance observed in these studies although statistically 
significant are relatively small and of debatable clinical significance. The findings by 
Sterling are in keeping with those of Saunders et al^  ^who have also investigated the 
effects of acute hypoxia on lung mechanics. In seven normal subjects (3 smokers) 
they examined the effect of acute isocapnic hypoxia (Fi02 40-50 mm Hg) on lung 
volumes and specific conductance of the lung over a twenty minute period employing 
a rebreathing method to produce hypoxia in their subjects. Saunders et al like 
Sterling observed a significant fall in specific lung conductance in keeping with a 
bronchoconstrictor effect. This was reversed when subjects began to inspire room air 
again. In addition to the changes in airway resistance they also found significant 
increases in total lung capacity, residual volume and functional residual capacity in 
their subjects breathing the hypoxic gas mixture. This observation may reflect 
premature airway closure in these subjects. It has been suggested by some groups that 
the apparent increase in airway resistance associated with acute hypoxia can be 
accounted for by an increase in vocal cord abduction during expiration rather than 
reflecting a true change in intrathoracic airway calibre. England et al^ °^  suggested
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that in normal subjects isocapnic hypoxia caused a significant increase in expiratory 
glottic narrowing when compared to normoxic breathing and that this increase in 
laryngeal airflow resistance was mistakenly interpreted as bronchoconstriction.
To add to the confusion, recent studies have even suggested that acute isocapnic 
hypoxia may cause tracheal and bronchial dilation in normal subjects. Julia-serda et 
al^ °^  examined the effect of acute isocapnic hypoxia on the cross sectional area of the 
pharynx, extrathoracic trachea, intrathoracic trachea and main bronchi using an 
acoustic reflection technique in 15 normal volunteers. They sequentially lowered the 
subjects oxygen saturation to between 80-85% and then 70-75% using a rebreathing 
method whilst maintaining constant end-tidal carbon dioxide levels. The cross 
sectional areas of the intra and extra thoracic trachea and the main bronchi increased 
significantly (p<0.001) on the hypoxic study days at both oxygen saturations when 
compared to the normoxic study days. No significant changes were found in the cross 
sectional measurements of the pharyngeal and glottic regions. This effect could not 
be reproduced by acute isocapnic hyperventilation suggesting that changes in the 
ventilatory pattern alone do not account for these findings.
Very few studies have examined the effect of acute hyperoxia on airway tone in 
normal subjects. The majority of studies examining the effects of hyperoxia on 
pulmonary physiology have focused on the pulmonary toxicity of hyperoxia over 
prolonged periods rather than its acute effects on airway tone. Wollner et al^ °^  and 
Inoue et al^ °^  were unable to demonstrate any significant change in FEVi after 
inspiring oxygen tensions of 100% and 30% respectively over a period of 10 minutes 
in patients with asthma. Libby et al^ '^^  in a study of 10 asymptomatic non-smokers
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were also unable to demonstrate any change in maximum expiratory flow volume 
curves after breathing 30% oxygen over a period of twenty minutes. A study 
examining the effect of inhaling a hyperoxic gas mixture (FiOi > 95%) for twelve 
hours, in eight healthy non-smoking males, found a significant fall in forced vital 
capacity at 4, 8 and 12 hours during exposure which persisted for 12 hours after 
exposure when compared to the same group breathing air.^ ^^
Studies have however examined the effect of acute hyperoxia on airway tone in 
patients with chronic hypoxia. Libby et al^ '^^  studied 12 patients with severe chronic 
obstructive pulmonary disease (mean FEVi 25% of predicted) and chronic hypoxia 
(mean PaOz at rest 61 mm Hg) all of whom had a history of heavy cigarette use. All 
of the patients experienced a significant improvement in their mean expiratory flow 
volume curves in keeping with bronchodilation after breathing 30% oxygen for a 
period of twenty minutes. The main conclusions from this work were that chronic 
hypoxaemia acted as a bronchoconstrictor in patients with chronic obstructive 
pulmonary disease and that reversal of hypoxia led to significant increases in airway 
calibre. This confirmed the earlier work of Astin^^  ^who studied 13 male patients 
with chronic hypoxia from chronic bronchitis and emphysema. He showed a 
significant fall (p<0.001) in airway resistance after breathing a gas mixture with 30% 
oxygen for 20 minutes and that the fall in airway resistance correlated strongly with 
the rise in oxygen saturation and not to changes in arterial carbon dioxide levels. He 
thought it was likely that this changes was due to a reflex mechanism rather than any 
direct action of oxygen on smooth muscle itself.
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1.5.2 Summary
Once again it is apparent that acute alterations in oxygen tension have effects on 
resting airway tone in man, but that the observations from a number of studies have 
produced rather conflicting results. It is difficult to make comparisons between 
studies because of the differences in study protocols, inspired oxygen tensions and 
methods used to measure airway calibre.
1.5.3 Effects on non-specific bronchial reactivity
Interest in the effects of acute alterations in oxygen tension on bronchial reactivity to 
non-specific pharmacological and physical challenges in patients with asthma have 
been stimulated by observations made in animals that hypoxia may potentiate and 
hyperoxia attenuate bronchial reactivity. The small number of studies which have 
examined this effect in patients with asthma have provided conflicting results. The 
effect of hypoxia and hyperoxia on constrictor and dilator stimuli in patients with 
asthma may be of importance during acute exacerbations.
Recent studies examining the effect of hyperoxia on methacholine induced 
bronchoconstriction have provided very different results. Inoue et al^ °^  suggested that 
in patients with asthma, breathing an inspired oxygen tension of 30% significantly 
attenuated the effect of methacholine on airway constriction whereas Wollner et al^ ^^  
concluded that an inspired oxygen tension of 100% had no effect on methacholine 
induced bronchoconstriction. It is difficult to compare these studies as they have used 
different inspired oxygen tensions and examination of their patient characteristics 
shows differences in the severity of asthma and the treatment that patients were
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receiving. In addition the study by Inoue et al was performed in a single blind fashion 
and 25% of patients had resting hypoxaemia.
Hyperoxia has also been shown to attenuate exercise induced bronchoconstriction in 
patients with asthma. The mechanism of this effect remanis controversial. Schiffman 
et al^ ®^  found that in asthmatic patients who had previously undergone bilateral 
carotid body resection hyperoxia did not attenuate airway constriction as had been 
found in asthmatic patients with intact carotid bodies. They suggested that hyperoxia 
acted directly on carotid chemoreceptors to reduce airway tone and hence oppose the 
typical bronchoconstrictor effect of exercise. Resnick et al^ ^^  however observed that 
in asthmatic patients who exercised whilst breathing oxygen (Fi0 2  100%) the rise in 
minute ventilation was smaller than that seen in the same group who exercised 
breathing air (Fi02 21%). They concluded that the reduction in airway constriction 
seen following exercise in patients with asthma who were breathing oxygen was due 
to a reduction in respiratory heat loss as a direct result of the fall in minute 
ventilation.
The results of studies examining the effect of acute hypoxia on non-specific bronchial 
reactivity have also provided conflicting results. In 1988 Denjean et af^ reported that 
lowering the inspired oxygen tension to 15%, whilst maintaining isocapnia in ten 
adults with asthma (4 female), significantly increased airway reactivity to 
methacholine. Hypoxia itself had no effect on baseline airway tone nor did it alter 
plasma catecholamine levels. The mechanism of this effect remains unexplained 
although Denjean et al suggested that hypoxia may act directly on smooth muscle 
cells to cause constriction, may precipitate release of constrictor mediators from cells
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within the airways or cause airway constriction as part of a reflex arc mediated via the 
carotid chemoreceptors. Interestingly however Tam et al^ ^^  were unable to 
demonstrate any differences in bronchoconstrictor responses to dry air in 15 patients 
with asthma whilst breathing a hypoxic gas mixture. It is worth noting however in 
this study an inspired oxygen tension of 8% was used to produce an oxygen saturation 
in their subjects of less than 80%. They observed in their subjects a significant 
increase in heart rate on the hypoxic study day in keeping with a rise in sympathetic 
output. This rise in sympathetic output to the airways causing bronchodilation may 
have offset any bronchoconstrictor effect of hypoxia alone which may have been 
observed with dry air challenge in their subjects.
1.5.4 Summary
In summary, studies have suggested that the properties of inspired gases, particularily 
oxygen tension, may influence the effects of non-specific bronchial challenge on 
airway tone in patients in asthma although the results of limited studies performed to 
date are somewhat controversial. There is evidence to suggest that hyperoxia may 
well attenuate and hypoxia potentiate bronchial reactivity in patients with stable 
asthma. Such an observation could have significant implications for patients with 
asthma who become hypoxaemic during an acute exacerbation.
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1.6 Hypothesis and Aims of Current Studies
Ambient oxygen tension has an important role in modulating the effects of constrictor 
and dilator stimuli on airway smooth muscle tone and in-vivo in
animals. In patients with asthma little is known about the effect of altering 
inspired oxygen tension on airway responses to bronchoconstrictor and bronchodilator 
stimuli and what reports are available have provided conflicting results. In patients 
with asthma hyperoxia appears to relieve exercise induced bronchoconstriction. 
Airway hyperresponsiveness to methacholine may be attenuated^®  ^or unaffected by 
hyperoxia. Eucapnic hypoxia has been shown to enhance airway 
hyperresponsiveness to methacholine^^but have no effect on airway response to dry 
air.^ ^^  To date no consensus has been reached and any comparison between these 
studies is confounded by differences in study protocols, patients studied and inspired 
oxygen tensions used. In addition most studies have failed to control adequately for 
the potential influences of circulating humoral factors or neural innervation of airway 
smooth muscle.
The hypothesis underlying this thesis is that acute alterations in oxygen tension will 
have an important role in modulating airway responses to constrictor and dilator 
stimuli in patients with asthma. Such observations may have relevance in patients 
admitted to hospital with acute exacerbations of asthma who are often 
hypoxaemic^ '^^^ and are given high inspired oxygen tensions to inhale in addition to 
both nebulised and intravenous bronchodilators. Using a common study design, in our 
in-vivo studies, we will investigate the interaction between oxygen tension and airway 
responses to constrictor and dilator stimuli in patients with mild stable asthma. We
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will investigate the potential influences of circulating humoral factors, carotid 
chemoreceptor activity, hypocapnia and altered ventilation patterns in our patients. 
The aims of our current studies are:
1. To develop a closed breathing circuit capable of delivering tightly controlled 
inspired oxygen tensions to patients with mild asthma.
2. To determine a level of inspired oxygen which produces moderate hypoxaemia, in 
our patients with asthma, without the unwanted effects of increased minute 
ventilation or altered carotid chemoreceptor activity which may accompany 
breathing low and high inspired oxygen tensions.
3. To investigate the effects of hypoxia (O2 tension 4%), normoxia (O2 tension 20%) 
and hyperoxia (O2 tension 95%) on airway tone in human isolated bronchial rings 
following incubation with histamine, methacholine and salbutamol.
4. To investigate the effects of breathing high and low inspired oxygen tensions on 
methacholine and histamine induced bronchoconstriction in patients with mild 
stable asthma.
5. To investigate the effects of breathing high and low inspired oxygen tensions on 
salbutamol induced relaxation of airway tone in patients with asthma.
As we have stated such observations may have relevance in the management of 
patients with acute exacerbations of asthma who are often hypoxaemic and receive 
high inspired oxygen tensions to breathe in addition to both nebulised and intravenous 
bronchodilators following admission to hospital.
CHAPTER 2 
GENERAL METHODS AND MEASUREMENTS
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2.1 Subjects
Normal subjects were recruited from the medical staff within the Department of 
Respiratory Medicine of the West Glasgow Hospitals University NHS Trust. All 
were non smokers and none were receiving any routine medication. None of the 
normal subjects had any significant cardiovascular or respiratory past medical history. 
Asthmatic patients were recruited directly from the asthma clinic of Professor N C 
Thomson or from a patient database held within the Asthma Research Unit of the 
West Glasgow Hospitals University NHS Trust. Summary details of normal subjects 
and patients for each study are provided in table form within the relevant chapters.
2.2 Spirometry
Measurements of forced expiratory volume in one second (FEVi) were made using a 
dry wedge spirometer (Vitalograph S, Vitalograph, Buckinghamshire, United 
Kingdom) which was calibrated prior to use on each study day. With the patient 
sitting comfortably the best FEVi from three attempts was recorded. Volumes were 
corrected for body temperature, pressure and saturation of water vapour (BTPS). 
Predicted values were taken from Knudsen et al.^ ^^
2.3 Measurement of heart rate, oxygen saturation, respiratory rate, inspired and 
expired oxygen and carbon dioxide levels
Heart rate and oxygen saturation were measured using a pulse oximetry probe placed 
on the subjects index finger (Datex Division of Instrumentarium Corp, Helsinki, 
Finland). A side port on the facemask worn during the study, allowed continuous 
sampling of the subjects inspired and expired gases and measurement of respiratory 
rate. The gases were analysed using an OSCARoxy TM multigas monitor (Datex of
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Instrumentarium Corp, Finland, Helsinki). The multigas gas analyser was calibrated 
during each study using gases of predetermined concentration supplied by Datex of 
Instrumentarium Corp. Recordings of each of the above observations were made 
every ten seconds for one minute at predetermined time points during study days.
The recordings were automatically printed by a Hewlett Packard Think Jet printer in a 
blind fashion for analysis after the study had been completed.
2.4 Blood pressure
Systolic, diastolic and mean arterial blood pressure were measured using a semi­
automatic sphygmomanometer (Dinamap®, 1846 FX vital signs monitor, Critikon, 
Berkshire, UK). The results of three similar readings at each time point were 
averaged to give a single value which was subsequently used for statistical analysis. 
Recordings were made every 3 minutes throughout the study in chapter 4.
2.5 Methacholine and histamine inhalation challenges
Patients performed methacholine and histamine inhalational challenges at the same 
time of day during each study. Patients were asked to withhold their short acting (32- 
agonists for 8 hours and long acting (32-agonists for 24 hours, prior to the study day. 
Slow release oral theophyllines were withheld for 48 hours before each day. Inhaled 
corticosteroids were continued as normal throughout the study period. Bronchial 
reactivity to methacholine and histamine was measured according to the technique 
described by Cockcroft et al and Hargreaves et Baseline FEVi was measured
until reproducible within 5%. Thereafter a saline inhalation challenge was 
administered and FEVi measured at 30, 90 and 180 seconds. The lowest post-saline
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value was taken as a baseline from which subsequent falls were measured. Doubling 
doses of nebulised histamine [histamine diphosphate monohydrate (Fluka Chemie, 
Gillingham, Dorset) made up in phosphate buffered normal saline] or methacholine 
[acetyl-B-methyl choline chloride (Sigma Chemical Company, Poole, Dorset, UK) 
made up in phosphate buffered normal saline] were then administered at five minute 
intervals. Each concentration was given for two minutes via a nebuliser (Micro-cirrus 
nebuliser, Intersurgical Ltd, Crane House, Wokingham, Berkshire) driven at a flow 
rate of 6 or 7 litres per minute by oxygen (100%), air (21%) or a hypoxic gas mixture 
(15%), from dedicated cylinders (British Oxygen Corporation, Medical gases) with an 
output of 0.12 or 0.11 mls/min. The aerosol solution from the micro-cirrus nebuliser 
(Intersurgical Ltd, crane House, Wokingham, Berkshire) was delivered to the patient 
through a port in the tight fitting aircraft face mask worn on all study days by the 
patients. The FEVi was measured at 0.5, 1.5 and 3 minutes after each nébulisation 
until a fall in FEVi of at least 20% was achieved as determine by linear interpolation 
from the logarithmic dose-response curve. This result was then expressed as the 
histamine or methacholine PC20 (provocation concentration 20%). At the end of each 
inhalation challenge patients received nebulised salbutamol to reverse any persisting 
bronchoconstriction. The histamine and methacholine solutions were made up by the 
sterile unit of the West Glasgow Hospitals University NHS Trust pharmacy 
department.
2.6 Oxygen breathing cireult
Precise inspired oxygen tensions for the patients to breathe were generated by passing 
oxygen (G size cylinders 3400 litres capacity from British Oxygen Corporation, 
Medical gases) and nitrogen (British Oxygen Corporation, Medical gases) contained
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in separate cylinders, through a Quantiflex air/oxygen flowmixer (model A-O, 
Cyprane Ltd, Keighly, Yorkshire). The gases generated from the flowmixer were 
passed via elephant tubing to a calibrated flowhead and a five litre rebreathing bag. 
Elephant tubing then ran from the rebreathing bag to a two way breathing valve 
attached to a tight fitting aircraft facemask (Thomas Respiratory Systems, London) 
which the patient breathed from throughout the study day. Dry gases which had not 
been humidified were used for all of the in-vivo studies. On study days patients, prior 
to performing an FEV%^  were asked to take a full inspiratory breath from the 5 litre 
rebreathing bag. The facemask was removed and patients blew into the spirometer 
before having the facemask reattached before performing the next FEVi. This 
minimised the amount of time patients were breathing ambient air.
2.7 Nebuliser output
The nebuliser output was calculated at different flow rates for each oxygen tension 
(0% 100%, 21% and 15%) used in the in-vivo studies, to ensure that the nebuliser 
output was the same for each study gas. The nebuliser (Micro-cirrus nebuliser, 
Intersurgical Ltd, Crane House, Wokingham, Berkshire) was driven by oxygen of 
different tensions from dedicated cylinders (British Oxygen Corporation, Medical 
gases). Prior to the in-vivo studies the nebuliser output was determined at flow rates 
of 5, 6, 7 and 8 litres per minute for oxygen tensions of 100%, 21% and 15%. The 
nebuliser was filled with 5 mis of normal saline and weighed. After 2 minutes of 
nébulisation the nebuliser was weighed again and the output in mls/min was 
calculated. This manoeuvre was repeated for each flow rate at each oxygen tension 
(figure 2.1).
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2.8 Adrenaline and noradrenaline assays
All hormone assays were performed by Dr J Morton of the Department of Medicine 
and Therapeutics in the West Glasgow Hospitals University NHS Trust. 5mls of 
venous blood were withdrawn, from a venous catheter, into chilled lithium heparin 
tubes. These samples were kept on ice until centrifugation at 4° centigrade following 
completion of the study day. Plasma adrenaline and noradrenaline levels were then 
measured using reverse phase high performance liquid chromatography and 
electrochemical detection after extraction of adrenaline and noradrenaline from 
plasma using activated alumina as described by Goldstein et al.^ ^^  The coefficient of 
variation for this technique is less than 10% and normal values are < 5.0 nmol/1 and < 
0.4 nmol/1 for noradrenaline and adrenaline respectively.
2.9 Drugs
Salbutamol: Ventolin® solution for nébulisation. Concentrations of 0.05mg/ml,
0.17mg/ml and 5.0mg/ml were prepared by the sterile supplies unit of the West 
Glasgow Hospitals University NHS trust in 3.0ml ampuoles.
Histamine; histamine diphosphate monohydrate (Fluka Chemie, Gillingham, Dorset, 
UK) for inhalational challenge made up in phosphate buffered saline to pH 7.4 was 
prepared by our pharmacy sterile supplies department.
Methacholine: acetyl-B-methyl choline chloride (Sigma Chemical Company, Poole, 
Dorset, UK) for inhalational challenge made up in phosphate buffered saline to pH
7.4 was prepared by our pharmacy sterile supplies department.
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2.10 Statistical analysis
Statistical analysis for the in-vivo and in-vitro studies were performed using an Apple 
Mackintosh LC II computer. For the in-vivo studies a Statview software package 
(Brainpower Inc, 24009 Ventura Boulevard, Suite 250, Calabasas) was used. For the 
in-vitro studies statistical analysis was performed using a minitab statistical package. 
For all studies a p value of < 0.05 was accepted as significant. Specific details 
relating to the statistical analysis are contained within the methods section of each 
paper.
2.11 Ethical approval
All of the study protocols described in this thesis had prior approval of the ethical 
committee for the West Glasgow Hospitals University NHS Trust. All of the patients 
gave written informed consent to the studies they participated in.
The raw data for this chapter is included in the Appendix (table 1 A)
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Illustration 1 : Picture of asthma subject using the oxygen breathing circuit.
Key: 1. Dry Wedge Spirometer
2. Curtain for blinding
3. Aircraft Facemask
4. Two-way Breathing Valve
5. Subject
6. 5 litreRebreathing Bag
7. Pulse Oximetry Probe
8. Nitrogen Cylinder
9. Quantiflex air/oxygen Flowmixer
10. G Size Oxygen Cylinder
11. OSCARoxy TM Multigas Monitor
12. Oxygen Cylinders to Drive Nebulisers
CHAPTER 3 
THE EFFECT OF ACUTE ALTERATIONS IN 
OXYGEN TENSION ON AIRWAY RESPONSES 
TO METHACHOLINE, HISTAMINE AND 
SALBUTAMOL IN HUMAN ISOLATED 
BRONCHIAL RINGS
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3.1 Introduction
Our first study was stimulated by in-vitro observations we had made in our own 
laboratory which had suggested that acute alterations in ambient oxygen tension 
significantly affected the response of airway smooth muscle to both 
bronchoconstrictor and bronchodilator stimuli/ '^^ '^^^ We had found that hypoxia (4% 
O2) potentiated the constrictor effects of both methacholine^^ and endothelin-1^^ in 
bovine isolated bronchial rings, but attenuated the response to methacholine in rat 
isolated bronchial rings/^ In bovine isolated bronchial rings the ability of salbutamol 
to relax airway smooth muscle preconstricted with methacholine was significantly 
attenuated by hypoxia (4% O2) and potentiated by hyperoxia (95% O2) when 
compared the normoxia (O2 20%)/^ We were aware that if these observations could 
be demonstrated in man then they might have relevance in the management of 
patients with acute exacerbations of asthma admitted to hospital who are commonly 
hypoxaemic. As part of their routine management such patients receive high inspired 
oxygen tensions to inhale as well as nebulised and intravenous bronchodilators. This 
first study was designed therefore to examine the effect of acute alterations in 
ambient oxygen tension on histamine and methacholine induced constriction and 
salbutamol induced relaxation of human isolated bronchial rings.
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3.2 Materials and methods
Tissue collection and preparation
Macroscopically normal human bronchi (2nd to 4th order, internal diameter 3-5mm) 
were obtained from non-asthmatic patients undergoing elective thoracic surgery.
Tissues were dissected free of connective tissue and fat and stored overnight at 4‘^ C in 
oxygenated Krebs-Henseleit solution of the following composition (mM), NaCl 
118.4, KCl 4.7, CaCls 2.5, MgS0 4  1 .2 , NaHCOj 24.9, KH2PO4 1.2 and glucose 11.1. 
Published data has shown that the overnight storage of this tissue does not alter its 
reactivity.
Measurement of contractile responses
Bronchial rings were suspended in vertical organ baths (10ml) at 37(+/-0.5)^C in 
oxygenated (95% O2, 5% CO2) Krebs-Henseleit solution. Resting tension of 2g wt was 
applied via two stainless steel wires inserted into the lumen. One wire was anchored and 
the other attached to a force displacement transducer (Grass FT03T) to measure isometric 
changes in tension. Tissues were allowed to equilibrate for 45 minutes, during which 
time tension was reapplied where necessary. The concentration of O2 in the gas mixture 
was reduced from 95% to 20% or 4% by substituting O2 with nitrogen. The oxygen 
tension of the solution was measured directly using a Jencons oxygen probe placed in the 
organ bath. Concentrations of O2 reached steady state in the organ baths within 2-3 
minutes. Gas mixtures containing 95%, 20% and 4% O2, produced O2 tensions of 524, 
147 and 26 mm Hg, respectively. The pH was buffered to 7.4 by the inclusion of 5%
CO2. A Mettler pH meter was used to measure the pH of the solution in the organ baths. 
The oxygen tension and pH of each organ bath was maintained at the appropriate value 
by altering the gas flow where necessary. Prior to the methacholine and histamine studies
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the viability of each ring was ascertained by the addition of a single concentration ( 1 0  ^
M) of methacholine to evoke a reference contractile response. Once the response had 
reached a plateau the vessels were then washed 3 times with Krebs-Henseleit solution and 
allowed to return to baseline tensions. Tensions were then adjusted if necessary and the 
vessels left for a further 45 minutes before the addition of any other drugs. In the 
histamine and methacholine studies cumulative concentration-response curves (CCRCs) 
to histamine (10'^-3xl0 '^ M) and methacholine (10'^-3xl0’'^ M) were constructed in each of 
the O2 tensions. In the case of methacholine, three consecutive CCRCs each in a 
different O2 tension were conducted on the same bronchial ring. To avoid tachyphylaxis, 
only one concentration-response curve was conducted to histamine in each tissue, 
therefore the three different oxygen tensions were imposed upon three separate bronchial 
rings. In the salbutamol study tissues were pre-incubated with 3xlO"^mol/l methacholine 
(approximately the EC50 for methacholine in this tissue) and the contraction allowed to 
reach a plateau. Cumulative concentration-response curves were then constructed for 
salbutamol (10*^  - lO''^  mol/1). To avoid tachyphylaxis, only one concentration-response 
curve was conducted to salbutamol in each tissue, therefore once again three different 
oxygen tensions were imposed upon three separate bronchial rings. In each experiment 
one tissue acted as a time control to ensure that the methacholine-induced contraction 
was maintained. The orders in which the gas mixtures were used were randomised 
between study days.
Materials
Histamine, methacholine and salbutamol were all obtained from Sigma Chemical Co, 
United Kingdom. The concentration in the text refers to the salts, with the exception of
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salbutamol which is expressed as the base. Stock solutions of drugs were prepared in 
distilled water and subsequent dilutions made in Krebs-Henseleit solution.
Statistical analysis
Number of observations (n) refers to the number of individual patients from whom 
tissue was obtained and in each case, n=8. Results for the methacholine and 
histamine studies are expressed as the mean maximum response (mg wt) in each of 
the three oxygen tensions. The salbutamol results are expressed as the mean (SEM) 
percentage of the control mean maximum inhibition in hyperoxia. Statistical analysis 
was performed using a Minitab package. Significance between data points (mean 
maximum responses) was calculated by Students t- test. A probability of p<0.05 was 
considered to be statistically significant.
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3.3 Results
Methacholine in-vitro
Methacholine-evoked contractile responses in human isolated bronchial rings in a 
concentration-dependent manner. In both hyperoxia and normoxia responses to 
methacholine were initiated at between 10"^  and SxlO'^M and between SxlO'^M and 
10'  ^in hypoxia. Reducing the oxygen fraction in the gas mixture from 95% to 20% 
significantly attenuated the contractions evoked by methacholine. Lowering the 
oxygen tension further, from hyperoxic to hypoxic levels produced a further reduction 
in the contractile response to methacholine (responses in hyperoxia were significantly 
p<0.001 greater than responses in hypoxia). Responses to methacholine in normoxia 
were significantly p<0.01 greater than in hypoxia. The maximum response to 
methacholine in hyperoxia was not significantly different from the maximum 
response in normoxia (mean (SEM) maximum response to methacholine in hyperoxia 
at the lO'^ ^M level; 2015 ± 504 mg wt, in normoxia at the lO'^ ^M level; 1469 ± 609 mg 
wt). The mean (SEM) maximum response in hypoxia however was significantly less 
than in hyperoxia (p<0.01) and normoxia (p<0.05). The mean (SEM) maximum 
response in hypoxia at the 10"^  level was; 816 ± 321 mg wt. In the time control 
studies there was no significant differences between the three consecutive 
concentration-response curves to methacholine in hyperoxia indicating that the 
contractile responses to methacholine in this tissue were not altered by time (figure
3.1).
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Histamine in-vitro
Histamine induced concentration-dependent contractions of the human isolated 
bronchial rings. In each of the oxygen tensions, responses to histamine were initiated 
at between 10'  ^M and 3x10’^  M, indicating that changes in oxygen tension did not 
alter the sensitivity of the tissue to histamine. Throughout the whole concentration- 
response curve, contractions evoked by histamine were significantly (p<0.01 and 
p<0.001 for data sets, respectively) greater in hyperoxia than in normoxia or hypoxia, 
and responses in normoxia were significantly (p<0.05 for data sets) greater than in 
hypoxia (figure 3.2). There was however no significant difference in the mean 
maximum response mg wt (at a concentration of 3xlO '^M) between hyperoxia; 1995 ± 
509.7 mg wt and normoxia 1076.7 ± 347.4 mg wt, or between the maximum response 
in normoxia and hypoxia 683.3 + 199.2 mg wt. The maximum response in hyperoxia, 
however, was significantly (p<0.05 for data points) greater than the maximum 
response in hypoxia (figure 3.2).
Salbutamol in-vitro
Salbutamol evoked a marked, concentration dependent reversal of the methacholine- 
induced contraction. Under hyperoxic and hypoxic conditions, responses to 
salbutamol were initiated at between 3x10'^ mol/1 and 10'  ^mol/1 and between 10'  ^
mol/1 and 3x10'^ mol/1 in normoxia. Lowering the oxygen tension from 95% to 20% 
oxygen did not significantly alter the ability of salbutamol to reverse methacholine- 
induced tone (mean maximal inhibition at 10 '^  mol/1: 103.02 ± 9.04 % in hyperoxia 
and 74.07 ± 11.65 % in nonnoxia, n=8). In contrast, responses evoked by salbutamol
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were significantly (p<0,001 for data sets) attenuated in hypoxia when compared to 
hyperoxia (mean maximal inhibition at 10*^  mol/1: 103.02 ± 9.04 % in hyperoxia and 
59.36 ± 7.85 % in hypoxia, p<0.01 for all data points). Responses to salbutamol were 
also significantly (p<0.01 for data sets) less in hypoxia compared with normoxia, 
although there was no significant difference between the maximum responses (mean 
maximal inhibition at 10"^  mol/1: 74.07 ± 11.65 % in normoxia and 59.36 ± 7.85 % in 
hypoxia) (figure 3.3). The absolute amount of isometric tension (mg wt) evoked by a 
single concentration of methacholine did not differ significant between the three 
oxygen tensions. The absolute amount of isometric tension generated by a single 
dose of methacholine in each oxygen tension prior to incubation with salbutamol was: 
hyperoxia 761,3 ± 178.9 mg wt, normoxia 613.8 ± 156.2 mg wt and hypoxia 483.5 ± 
149.9 mg wt.
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3.4 Discussion
Our initial in-vitro studies have shown that acute hypoxia (O2 tension 4%) 
significantly attenuates the ability of both histamine and methacholine to constrict 
human isolated bronchial rings when compared to normoxia (O2 20%) and hyperoxia 
(O2 95%). In addition the ability of the bronchodilator salbutamol to relax human 
isolated bronchial rings is also significantly attenuated by hypoxia (O2 4%) when 
compared to normoxia (O2 20%) and hyperoxia (O2 95%).
The effect of hypoxia on histamine and methacholine induced constriction of airway 
smooth muscle in human isolated bronchial rings that we have found, differs from our 
original observations in bovine isolated bronchial rings constricted with methacholine 
and endothelin-1^^’^  ^ Such a fundamental difference in results is difficult to explain 
when we consider that the studies were undertaken in the same laboratory using 
identical materials, methods and oxygen tensions. This suggestion is perhaps 
supported by original observations in rat isolated bronchial rings which also suggested 
attenuation of methacholine induced contractions by hypoxia.^^ It would appear 
therefore that bovine airway smooth muscle behaves differently in hypoxia when 
compared to rat and human tissue.
Our results are however in keeping with several other groups who have reported 
hypoxic relaxation following non-specific challenge in airway smooth muscle from 
several other s p e c i e s . W h i l e  there is agreement that hypoxia causes 
impairment of airway smooth muscle constriction following non-specific challenge, 
considerable debate still rages over the mechanism of the effect and whether or not it 
is linear. Stephens et have suggested that hypoxia impairs mitochondrial
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function which impairs intracellular energy release and reduces the ability of airway 
smooth muscle to generate contractile forces. Vannier et al^  ^have suggested that the 
effect is linear with greatest relaxation at the lowest oxygen tensions. His group also 
demonstrated that hypoxic relaxation of porcine airway smooth muscle constricted 
with carbachol was abolished when the bronchial rings were incubated with BAY K 
8644, a L-type Ca2+ channel agonist suggesting that hypoxia impairs calcium entry 
into cells. They however were unable to show that the effect was abolished by 
removing the epithelium from the bronchial rings as had been shown by Gao and 
Vanhoutte.^^ Gao and Yanhoutte have suggested that the bronchial epithelium 
released an unidentified relaxing factor in response to hypoxia.
The observation of hypoxic relaxation has not been observed Several
groups have suggested that hypoxia potentiates airway smooth muscle contraction 
following pharmacological challenge. Suggested mechanisms include local release of 
inflammatory mediators^^’^ ’^^  ^and reflex bronchoconstriction as an indirect effect of 
hypoxia on carotid and peripheral chemoreceptors.^^’^  ^ It is worth noting that our 
bronchial rings are deprived of their normal circulating humoral factors and neural 
innervation allowing us to observe the true direct effects of hypoxia on airway smooth 
muscle. It must however be remembered that the ambient oxygen tensions used are 
significantly lower in-vitro than in-vivo and that this may influence our results.
Further in-vitro studies employing a range of oxygen tensions would allow us to form 
dose response curves to various constrictor stimuli at oxygen tensions which are 
similar to those we have used in our in-vivo studies.
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Our in-vitro studies have also shown that hypoxia impairs the ability of salbutamol to 
relax airway smooth muscle in human isolated bronchial rings. This has not 
previously been reported in the literature. It is however in keeping with our own in- 
vitro observations in bovine isolated bronchial rings.^ '^^^
In our study we have used a single concentration of methacholine (10 '6M) to 
preconstrict our bronchial rings prior to the addition of salbutamol. Although we 
have already suggested that hypoxia attenuates methacholine induced constriction in 
human isolated bronchial rings this effect is observed only when the full 
concentration-response curves are compared. No significant difference was observed 
in maximum isometric tension developed between each oxygen tension when a single 
concentration of methacholine was added to the organ baths. We have not therefore 
made any adjustment to baseline tension prior to the addition of salbutamol. If 
however our hypoxic bronchial rings were less constricted at baseline then this may 
have contributed to our observation that salbutamol induced relaxation of human 
isolated bronchial rings is attenuated by hypoxia.
Our result is however somewhat surprising as it might be anticipated, that if hypoxia 
causes impairment of airway smooth muscle contraction as we have previously 
suggested then the ability of salbutamol to relax airway smooth muscle should if 
anything be augmented by hypoxia. It would seem likely therefore that hypoxia has 
other effects which impair the ability of salbutamol to relax airway smooth muscle. 
Hypoxia has been reported to cause down regulation of cardiac 5 -recep torsand  
uncoupling of 5-adrenoceptors from their regulatory G-proteins.^^^ Both of these 
observations could explain our in-vitro findings. Hypoxia also induces opening of
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membrane-bound potassium channels in isolated bronchial rings. Salbutamol 
mediates smooth muscle relaxation by opening these channels. If the majority of
these channels were already open, as they almost certainly would be at an ambient 
oxygen tension of 4%, the effectiveness of salbutamol to relax the bronchial rings 
would be significantly impaired. Our in-vitro observations may have particular 
relevance to hypoxaemic patients with acute exacerbations of asthma who receive 
nebulised and intravenous bronchodilators. It however must be remembered that we 
have used very profound levels of hypoxia in our in-vitro studies, which could not be 
used to in-vivo in patients with asthma. However our in-vitro findings to date, 
suggest that it would be interesting to examine the effect of acute alterations in 
oxygen tension on both constrictor and dilator stimuli in patients with asthma.
In conclusion our initial in-vitro studies have suggested that hypoxia significantly 
attenuates methacholine and histamine-induced constriction and salbuatmol induced 
relaxation in human isolated bronchial rings.
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Fig 3.1 Contractions evoked by methacholine in human isolated bronchi in 
hyperoxia, normoxia and hypoxia. Methacholine was added cumulatively to give 
final bath concentrations of 10'^  x 3xlO'^M. Responses are expressed in mg wt. 
Methacholine was significantly (P<0.05 and P<0.001 respectively) more effective in 
hyperoxia than in normoxia and hypoxia and significantly (P<0.01) more effective in 
normoxia than in hypoxia. Number of observations (n)=8 in each case.
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Fig 3.2 Contractions evoked by histamine in human isolated bronchi in hyperoxia, 
normoxia and hypoxia. Histamine was added cumulatively to give final bath 
concentrations of 10  ^x 3xlO^M. Responses are expressed in mg wt. Histamine was 
significantly (P<0.01 and P<0.001 respectively) more effective in hyperoxia than in 
normoxia and hypoxia and significantly (P<0.05) more effective in normoxia than in 
hypoxia. Number of observations (n)=8 in each case.
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Fig 3.3 The ability of salbutamol to reverse methacholine-induced tone in human 
isolated bronchi in hyperoxia, normoxia and hypoxia. Salbutamol was added 
cumulatively to give final bath concentrations of 10 ^  - lO'^M. Responses are 
expressed as a percentage reversal of the methacholine contraction. Salbutamol was 
significantly (P<0.001) more effective in hyperoxia than in hypoxia and significantly 
(P<0.01) more effective in normoxia than in hypoxia. Number of observations (n)=8 
in each case.
CHAPTER 4 
THE EFFECT OF ACUTE CHANGES IN 
INSPIRED OXYGEN TENSION ON 
VENTILATORY AND CARDIOVASCULAR 
RESPONSES IN NORMAL SUBJECTS USING A 
NOVEL CLOSED BREATHING CIRCUIT
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4.1 Introduction
The effects of acute alterations in inspired oxygen tension, on cardiovascular and 
respiratory responses, have been extensively studied in both animals and man for 
more than one hundred years. Despite the considerable resources which have
been employed in these investigations, controversy about the effects still exist in 
some areas, particularly the effects of hypoxia and hyperoxia on airway tone in-vivo 
in man.^ "^^ '^^ °^  For the purposes of this thesis our interest lies not in the direct effect 
of acute alterations in oxygen tension on airway smooth muscle but the effects of 
acute hypoxia and hyperoxia on airway smooth muscle tone following inhalation of 
constrictor and dilator stimuli in patients with asthma. This interest has been 
stimulated by in-vitro observations from our own laboratory that suggest that the 
ambient oxygen tension of organ baths can significantly alter the effects of constrictor 
and dilator stimuli in human (chapters), bovine and rat isolated bronchial rings.^^’^  ^
We have hypothesised that acute alterations in oxygen tension may have an important 
role in-vivo in modulating the action of bronchoconstrictor and bronchodilator stimuli 
on airway tone and that this may have particular relevance to patients suffering an 
acute exacerbation of asthma. We have therefore designed a closed breathing circuit 
which allows us to closely control the inspired oxygen tension we can deliver to 
patients with asthma. The aim of our initial studies was to ensure that our closed 
breathing circuit was capable of producing and maintaining either a hypoxic or 
hyperoxic environment in which to conduct our future in-vivo investigations. In 
addition we wished to determine a level of inspired oxygen that would produce 
significant hypoxaemia in our patients without the unwanted additional effects of 
increased sympathetic activity which can accompany hypoxaemia^^’^ ^^ ’^^  ^ and which 
may itself have indirect effects on airway tone which could influence the results of
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our in-vivo studies.
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4.2 Subjects and methods 
Subjects
In the first study looking at the effect of hypoxia on cardiovascular and respiratory 
responses, seven non-smoking healthy subjects (all male) with a mean (SD) age of 31 
(8.5) years were recruited from the staff of the respiratory unit in Gartnavel General 
Hospital. In a second study looking at the effects of hyperoxia on cardiovascular and 
respiratory responses, eight non-smoking healthy subjects (6 males) with a mean (SD) 
age 33(3) years were also recruited from the staff of the respiratory unit. All subjects 
had an FEV] greater than 80% of predicted and no evidence of airflow obstruction. 
None of the subjects had a history of respiratory or cardiovascular disease and none 
were taking any routine medication. All of the subjects gave informed consent to the 
study which had previously been approved by the West Ethics Committee.
Study design
Study 1: Hypoxia in normal subjects
Subjects attended the laboratory on two study days. On the first study day simple 
spirometry was performed and a full medical history obtained. On a subsequent study 
day after 30 minutes of supine rest subjects were commenced on our closed breathing 
circuit (chapter 2.6). After 10 minutes breathing air (FiO  ^21%) baseline 
measurements of oxygen saturation (SaO%%), heart rate (HR), respiratory rate (RR), 
inspired oxygen and carbon dioxide levels (insp 0 2 %, insp 0 0 2 %), end-tidal oxygen 
and carbon dioxide levels (PET02%, PETC02%) and blood pressure (BP) were made. 
Subjects then inhaled inspired oxygen tensions of 21%, 18%, 15% and 12% 
sequentially for 12 minutes at each level in a single blind fashion.
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Study 2: Hyperoxia in normal subjects
Subjects attended the laboratory on two study days. On the first study day simple 
spirometry was performed and a full medical history obtained. In a second study 
following 30 minutes of supine rest patients breathed air (FiOz 21%) for 10 minutes 
through the closed breathing circuit following which the baseline measurements 
already described were made. The subjects then inhaled oxygen (FiOz 100%) or air 
(FiOz 21%) for 15 minutes each in a randomised double blind fashion. The 
measurements made at baseline were repeated every 3 minutes until completion of 
the study day. The oxygen and nitrogen cylinders and mixing valve were obscured 
from the subjects vision and the inspired oxygen tension was controlled by a second 
operator. The measurements made at baseline were repeated every 3 minutes until 
completion of the study day.
Measurements
Systolic, diastolic and mean arterial blood pressure were measured using a semi­
automatic sphygmomanometer (Dinamap®, 1846 FX vital signs monitor, Critikon, 
Berkshire, UK) -  see chapter 2.4.
Heart rate and oxygen saturation were measured using a pulse oximetry probe (Datex 
Division of Instrumentarium Corp, Helsinki, Finland) -  see chapter 2.3.
Respiratory rate, inspired and expired oxygen and carbon dioxide levels were 
measured using an OSCARoxy TM multigas monitor (Datex of Instrumentarium 
Corp, Finland, Helsinki) -  see chapter 2.3.
FEVi was measured using a dry wedge spirometer (Vitalograph S, Vitalograph, 
Buckinghamshire, United Kingdom) -  see chapter 2.2.
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Statistical analysis
Statistical analysis for this study was perfonned using an Apple Mackintosh LCII 
computer. A Statview software package (Brainpower Inc, 24009 Ventura Boulevard, 
Suite 250, Calabasas) was used. Analysis of Variance (ANOVA) corrected for 
multiple comparisons was used to compare differences between similar time points at 
each inspired oxygen tension and differences from baseline at each time point. A p 
value of < 0.05 was accepted as significant.
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4.3 Results
Study 1 Hypoxia in normal subjects
Oxygen saturation: Oxygen saturation was significantly lower (p<0.01) at 3, 6, 9 
and 12 minutes breathing FiOz 15% and 12% compared to baseline and inspired 
oxygen tensions of 21% and 18%. The oxygen saturation breathing FiOz 12% was 
also significantly lower at 3, 6, 9 and 12 minutes compared to the inspired oxygen 
tension 15%. There was no significant difference (p>0.05) in oxygen saturations 
breathing FiOz 21% compared to 18% (figure 4.1).
End-tidal COz% levels: End-tidal COz% levels were significantly lower (p<0.01) at 
all time points breathing an inspired oxygen tension of 12% compared to 21%, 18% 
and 15% (figure 4.2).
Respiratory rate: There were no significant differences (p>0.05) in respiratory rates 
at any time point between any of the inspired oxygen tensions or baseline, (figure
4.2).
Heart rate: Heart rate was significantly greater (p<0.01) breathing an inspired 
oxygen tension of 12% compared to 21%, 18%, 15% and baseline. There was no 
significant differences (p<0.05) in heart rate between any of the other inspired oxygen 
tensions at any time point (figure 4.1).
Diastolic blood pressure: Diastolic blood pressure was significantly lower (p<0.05) 
breathing an inspired oxygen tension of 12% compared to baseline and breathing FiOz 
21%, 18% and 15% at all time points.
Systolic and mean arterial blood pressure: There were no significant differences 
(p>0.05) in systolic and mean arterial blood pressures when comparing each of the 
inspired oxygen tensions to each other and baseline at any time point.
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Study 2 Hyperoxia in normal subjects
Oxygen saturation: Oxygen saturation was significantly higher (p<0.001) at all time 
points when subjects breathed oxygen (FiOz 100%) compared to air (FiOz 21%). 
Oxygen saturation breathing oxygen (FiOz 100%) was also significantly greater 
(p<0.001) than the oxygen saturation recorded at baseline (figure 4.3).
End-tidal COz% levels: End-tidal COz% levels were significantly lower (p<0.001) 
at 6,9, 12 and 15 minutes after breathing oxygen compared to breathing air. There 
was no significant difference (p>0,05) at 3 minutes. End-tidal COz% levels were also 
significantly lower at 6,9,12 and 15 minutes breathing oxygen compared to baseline 
(figure 4.4).
Respiratory rate: There were no significant differences (p>0.05) in respiratory rate 
at any time point when oxygen and air were compared (figure 4.4).
Heart rate: Heart rate was significantly lower (p<0.001) at all time points when 
breathing oxygen (FiOz 100%) compared to breathing air (FiOz 21%). Heart rate was 
also significantly lower (p<0.001) breathing oxygen compared to baseline (figure
4.3).
Systolic, diastolic and mean arterial blood pressure: There were no significant 
differences (p>0.05) in systolic, diastolic and mean arterial blood pressure when 
breathing oxygen was compared to breathing air at 3, 6, 9,12 and 15 minutes.
Raw data for this chapter is included in the appendix (tables 2A -  ISA)
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4.3 Discussion
In normal subjects, oxygen (FiOz 100%) inspired through our closed breathing circuit 
is associated with a rise in oxygen saturation, fall in end-tidal COz% levels and a 
reduction in heart rate compared to breathing air (FiOz 21%). The effects of hypoxia 
on cardiovascular and respiratory responses in nonnal subjects are more variable and 
clearly dependent on the inspired oxygen tension used. Oxygen saturation only fell 
significantly when patients inspired oxygen tensions of 15% and 12% when compared 
to breathing air (FiOz 21%). Inspiring an oxygen tension of 12% was also associated 
with a significant fall in end-tidal COz% levels, increases in heart rate and reduction 
in diastolic blood pressure compared to inspiring oxygen tensions of 21%, 18% and 
15%.
Our findings in normal subjects breathing oxygen (FiOz 100%) are similar to those of 
several other groups.^^’^ ^^ ’^ ^^  Jennet^ in her thesis from 1964 suggested a biphasic 
ventilatory response to breathing 100% oxygen. An initial rise in end-tidal COz% 
levels in the first 10-20 seconds was followed several minutes later by a more 
sustained fall in end-tidal COz% levels which persisted throughout the period subjects 
inspired 100% oxygen. She proposed that an initial fall in minute ventilation, 
reflected in the rise in end-tidal COz% levels, was mediated as part of a reflex arc 
stimulated by the direct effect of the high vascular oxygen tension on carotid 
chemoreceptors. The subsequent fall in end-tidal COz% levels reflected an increase 
in minute ventilation which occurred as a consequence of increased cerebral COz% 
levels which acted on central chemoreceptors in the respiratory centre which 
provoked an increase in respiratory rate which persisted throughout the period that 
subjects breathed 100% oxygen. She postulated that raised cerebral COz% levels
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occurred because of cerebral vasoconstriction as a consequence of a fall in cardiac 
output. The fall in cardiac output, detected in subjects breathing oxygen, was due to a 
fall in heart rate rather than any change in stroke volume. Jennet was however unable 
to show an increase in COz% levels in the internal jugular veins which one might 
have expected to see if this hypothesis was correct. We have also detected a 
significant fall in heart rate in our subjects breathing oxygen but no significant change 
in respiratory rate. While it is almost certain that the sustained fall in end-tidal COz% 
levels we have observed reflect an increase in minute ventilation, our findings would 
suggest that this is due to changes in tidal volume rather than respiratory rate. Green 
and Widdicombe^^ also observed a sustained fall in end-tidal 00%% levels in 
anaesthetised dogs breathing oxygen (FiOz 100%). They however suggested that the 
effect, which also took 4 minutes to fully develop in their models, was due to a reflex 
increase in vagal tone following stimulation of carotid chemoreceptors by 100% 
oxygen. This hypothesis was supported by the observation that the effect was 
abolished when the dogs were pre-treated with intravenous atropine. Like others^^  ^
we have also found a significant fall in heart rate in our subjects which occurs 
immediately. It has been suggested that stimulation of carotid chemoreceptors by 
100% oxygen results in increased vagal tone causing bradycardia and a subsequent 
fall in cardiac output. Once again this effect is blocked by the addition of intravenous 
atropine.
We have shown that in our normal subjects inspiring oxygen tensions of 12% and 
15% causes a significant fall in oxygen saturation in keeping with the presence of 
moderate hypoxaemia. However of more interest to us are the additional effects 
which occurred at an inspired oxygen tension of 12%. At this low inspired oxygen
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tension we have observed, in our healthy volunteers, a significant increase in heart 
rate, fall in diastolic blood pressure and reduced end-tidal 00^% levels. This would 
suggest significant stimulation of sympathetic nervous activity which is likely to be 
mediated through carotid and peripheral chemoreceptors. The changes we
have observed have been reported by many authors and are acknowledged to be 
mediated via carotid and aortic body chemoreceptors. It is believed that 
normoxaemia causes resting tonic activity in carotid chemoreceptors^^^’^ "^^ and that a 
rise in ambient oxygen tension results in a fall in tonic activity provoking increased 
vagal discharge. Conversely a fall in ambient oxygen tension increases tonic 
activity and results in increased sympathetic activity raising heart rate and increasing 
ventilation. Controversy however remains as to what level of hypoxaemia is 
required to provoke an increase in sympathetic activity in man. Comroe and 
Schmidt^^  ^have suggested a threshold arterial oxygen tension of 50 mm Hg is while 
others^^  ^have suggested that chemoreceptor activity is inversely related to the 
ambient oxygen tension of the chemoreceptor. Using our novel closed breathing
circuit we have found that an inspired oxygen tension between 15% and 1 2 % 
provokes an increase in sympathetic activity in our normal subjects and the pattern is 
similar to that reported by other groups. For this reason we plan to use an
inspired oxygen tension of 15% in which to conduct our hypoxic in-vivo studies 
because at that level we have provoked a significant fall in oxygen saturation in 
keeping with moderate hypoxaemia without the unwanted effects of sympathetic 
activation. We therefore would not anticipate any indirect effects of hypoxaemia on 
airway tone mediated via carotid and arterial chemoreceptors in our hypoxic studies 
which could potentially influence our results.
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In conclusion the changes in oxygen saturation, heart rate and end-tidal COz% levels 
that we have observed in our studies, would suggest that our novel closed breathing 
circuit has allowed us to deliver precisely controlled inspired oxygen tensions which 
have achieved significant changes in arterial and airway oxygen tensions. These 
studies were a necessary prerequisite prior to undertaking our planned in~vivo studies 
in patients with asthma. In addition it would appear that an inspired oxygen tension 
of 15% produces significant falls in oxygen saturation and arterial PaOz without 
stimulation of sympathetic activity, and will therefore be the inspired oxygen tension 
of choice for our hypoxic studies. We had already planned to use an inspired oxygen 
tension of 1 0 0 % in our hyperoxic studies to mimic the oxygen tensions used in our in- 
vitro studies.
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FEVi FVC
Subjects Age
(years)
Sex Absolute
(litres)
Predicted 
- (%)
Absolute
(litres)
Predicted
....... _(%!_ ___ __
1 27 M 4.83 97 6.07 99
2 49 M 3.48 88 4.30 92
3 46 M 3.62 103 4.38 98
4 28 M 3.96 82 5.01 86
5 28 M 4.50 100 5.51 104
6 23 M 4.78 112 5.34 106
7 24 M 4.18 85 5.18 91
Mean
(SEM)
32
(11)
4.19
(0.54)
5.11
(0.62)
Table 4.1 Characteristics of 7 normal subjects inhaling inspired oxygen tensions of 
2 1 %, 18%, 15% and 1 2 % for 1 2  minutes each.
FEVi FVC
Subjects Age
(years)
Sex Absolute
(litres)
Predicted
(%)
Absolute
(litres)
Predicted
(%)
1 28 M 3.96 82 5.01 86
2 44 F 3.60 118 4.00 136
3 46 M 3.62 103 4.38 98
4 27 M 4.83 97 6.07 99
5 25 M 4.42 93 5.30 97
6 49 M 3.48 88 4.30 92
7 29 F 3.17 103 3.81 107
8 28 M 4.60 90 5.48 96
Mean
(SEM)
33
(8.4)
3.85
(0.73)
4.79
(0.79)
Table 4.2 Characteristics of 8  normal subjects inhaling air (Fi0 2  21%) and oxygen 
(FiOz 1 0 0 %) for 15 minutes each.
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Fig 4.1 Heart rate (beats per minute) and oxygen saturation (Sa02% ) in normal 
subjects inhaling inspired oxygen tensions o f  21%, 18%, 15% and 12% for 12 
minutes each in a single blind fashion. (n=7)
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CHAPTER 5 
THE EFFECT OF ACUTE HYPEROXIA ON 
METHACHOLINE INDUCED 
BRONCHOCONSTRICTION IN PATIENTS WITH
MILD ASTHMA
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5.1 Introduction
The first of our in-vivo study was prompted by observations from our own laboratory 
that hyperoxia (O2 tension 95%) significantly attenuated the constrictor response of 
both methacholine and endothelin-1  in bovine isolated bronchial rings when 
compared to normoxia (O2 tension 20%) and hypoxia (O2 tension 4%)/^'^^ A review 
of the relevant literature revealed that similar findings had been made in-vivo in dogs 
where histamine induced tracheal constriction was reported to be inhibited by oxygen 
(Fi0 2  100%).^  ^ The effects of hyperoxia on airway responsiveness in asthma however 
are more uncertain. Previous studies had suggested that exercise induced 
bronchoconstriction was significantly attenuated by inhaling high inspired oxygen 
tensions although controversy persists about the potential mechanism of this 
effect. In patients with asthma methacholine inhalation challenge has been 
reported to be both attenuated^^^ or unaffected^®  ^by hyperoxia. If the administration 
of high concentrations of inspired oxygen can reduce the responsiveness of the 
airways to bronchoconstrictor stimuli in patients with asthma then this effect of 
oxygen may be of relevance in the treatment of acute exacerbations of asthma. Our 
first in-vivo study was designed to examine the effect of breathing oxygen (Fi02 
1 0 0 %) on methacholine-induced bronchoconstriction in patients with mild asthma.
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5.2 Patients and methods 
Patients
Fourteen adult mild asthmatic patients (five male) mean (SD) age 36 (9.2) years were 
recruited into the study (table 5.1). All had a history of asthma and an FEVi > 80% 
of predicted at a screening visit. None had any other significant illnesses. All 
patients were taking inhaled 6 2 -agonists on an as required basis. A further ten were 
on regular inhaled corticosteroids and of these two were taking regular oral 
theophyllines and one patient inhaled salmeterol. The research was carried out in 
accordance with the Declaration of Helsinki (1989) and all of the patients gave 
written informed consent to the study protocol which had the approval of the West 
Ethics Committee.
Study design
Patients attended the laboratory on three separate study days at approximately the 
same time each day. During the initial screening visit each patient underwent a 
methacholine inhalation challenge test to determine a PC20 value ie: that 
concentration of methacholine causing a 20% fall in FEVi. On the subsequent two 
days, after thirty minutes of supine rest, the patients were commenced on our closed 
breathing circuit. Following a ten minute run in period breathing air (Fi0 2  21%) 
baseline measurements of FEVi, respiratory rate (RR), heart rate (HR), oxygen 
saturation (Sa0 2 %) inspired oxygen and carbon dioxide levels (insp 0 2 %, insp 0 0 2 %) 
and expired oxygen and carbon dioxide levels (PET0 2 %, PETC0 2 %) were made. 
Venous blood was also taken for assay of plasma catecholamines. Patients were then 
administered either air (Fi02 2 1 %) or oxygen (Fi02 1 0 0 %) in a randomised double
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blind fashion for the remainder of the study day. A methacholine inhalation 
challenge was commenced ten minutes after starting the study gas. The study day 
was terminated when a PC2 0  value was reached and the measurements made at 
baseline had been repeated.
Measurements
Heart rate and oxygen saturation was measured using a pulse oximetry probe (Datex 
Division of Instrumentarium Corp, Helsinki, Finland) - see chapter 2.3.
Respiratory rate, inspired and expired oxygen and carbon dioxide levels were 
measured using an OSCARoxy TM multigas monitor (Datex of Instrumentarium 
Corp, Finland, Helsinki) - see chapter 2.3.
Methacholine PC20 value (mg/ml) was measured according to the technique described 
by Cockcroft et al and Hargreaves et -  see chapter 2.5.
FEVi was measured using a dry wedge spirometer (Vitalograph S, Vitalograph, 
Buckinghamshire, United Kingdom) - see chapter 2.2.
Plasma catecholamines were measured using reverse phase high performance liquid 
chromatography - see chapter 2 .8 .
Statistical analysis
Statistical analysis was performed on an Apple Mackintosh LC II computer using a 
Statview software package (Brainpower Inc, 24009 Ventura Boulevard, Suite 250, 
Calabasas). Paired T-tests were used to compare measurements between study days. 
The PC20 values were logarithmically transformed before analysis. A p-value below 
0.05 was accepted as significant.
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5.3 Results
Baseline measurements: There were no significant differences between baseline 
measurements of FEVi, heart rate, respiratory rate, oxygen saturation, end-tidal 
COz%, adrenaline and noradrenaline levels on the two study days.
Methacholine PC20 values: There were no significant differences in the geometric 
mean (range) PC20 values mg/ml between the normoxic and hyperoxic study days.
The geometric mean (range) PC20 value mg/ml on the normoxic day was 0.96 (0.02 -  
10.6) mg/ml compared to 1.38 (0.13 -  15.9) mg/ml on the hyperoxic study day (figure 
5.1).
Oxygen saturation: Oxygen saturation was significantly higher (p<0.01) following 
hyperoxia [mean (SEM) Sa0 2 %: baseline 96.7 (0.35)%, pre-methacholine 98.1 
(0.23)%, post-methacholine 98.1 (0.20)%] than during the normoxic study day [mean 
(SEM) Sa0 2 %: baseline 96.5 (0.33)%, pre-methacholine 96.7 (0.37)%, post- 
methacholine 96.0 (0.52)%] (figure 5.2).
Heart rate: Heart rate was significantly lower (p<0.05) on the hyperoxic study day 
both before and after the methacholine inhalation test when compared to the 
normoxic study day. The mean (SEM) HR (bpm) on the hyperoxic study day was: 
baseline 75 (4) bpm, pre-methacholine 71 (4) bpm, post-methacholine 71 (4) bpm 
and on the normoxic study day: baseline 77 (4) bpm, pre-methacholine 75 (5) bpm, 
post-methacholine 77 (4) bpm (figure 5.2).
£nd-tidal €0%%: There was a significant (p<0.05) fall in PETC0 2 % on both study 
days, before and after methacholine inhalation when compared to baseline but no 
significant difference in PETC0 2 % between the study days . The mean maximum
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(SEM) reduction in PETC0 2 % during the normoxic day was 0.56 (0.16)% and 0.60 
(0.13)% on the hyperoxic day (figure 5.2).
Catecholamine levels: The circulating plasma noradrenaline levels (n=12) on the 
normoxic study day were [mean (SEM) noradrenaline nmol/1: baseline 2.14 (0.58) 
nmol/1, post-methacholine 1 .6 6  (0,28) nmol/1] were not statistically different from the 
hyperoxic study day [mean (SEM) noradrenaline mnol/1: baseline 1.80 (0.26) nmol/1, 
post-methacholine 1.63 (0.28) nmol/1]. Plasma adrenaline levels (n=12) on the 
normoxic study day were [mean (SEM) adrenaline nmol/1: baseline 0.11 (0.02) 
nmol/1, post-methacholine 0.07 (0.02) nmol/1] were also no different from the 
hyperoxic study day [mean (SEM) adrenaline nmol/1: baseline 0.07 (0.02) nmol/1, 
post-methacholine 0.07 (0.02) nmol/1].
Respiratory rate: There were no significant differences in respiratory rate on either 
study day at any time point (data not shown).
Raw data for this chapter is included in the Appendix (tables 16A - 17A)
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5.4 Discussion
These results demonstrate that acute hyperoxia does not attenuate methacholine- 
induced bronchoconstriction in~vivo in mild asthmatic patients. This result clearly 
differs from both the in-vitro work from our own laboratory^^’^  ^and the in-vivo 
animal studies we have discussed earlier.
It is in the first instance worth reconsidering our own study design to ensure that our 
hypothesis has been appropriately tested before postulating on more profound reasons 
for the differences in the results we have observed. The rise in oxygen saturation and 
fall in heart rate^^ ’^^ ^^  we have noted in our patients would suggest that significant 
increases in airway and arterial oxygen tensions have been obtained from our closed 
breathing circuit. The absence of any difference in end-tidal 00%% between study 
days at any time point indicates that hypocapnic bronchoconstriction/^^"^^^ as a 
consequence of hyperoxia/w as not a confounding factor in our results. Nebuliser 
output, which may be affected by the molecular weight of the gas used to drive the 
nebuliser, was prior to the commencement of the study confirmed to be 0 .1 2  mls/min 
at a flow rate of 6  litres per minute for both study gases (FiOi 1 0 0 % and Fi0 2  2 1 % )- 
chapter 2.7. This would suggest that patients received the same quantity of 
methacholine from each nébulisation. Circulating adrenaline and noradrenaline have 
effects on airway smooth muscle tone,^ "^  In the present study we observed no 
difference in circulating catecholamine levels on either study day both before and 
after methacholine challenge.
8 2
There are several possible reasons why the results of our study are in contrast to the 
findings of both the in-vitro and in-vivo animal studies which reported that hyperoxia
*7^ CQattenuates airway reactivity. ’ ’ While hyperoxia attenuates the bronchoconstrictor 
effect of methacholine and endothelin-1  in isolated bovine bronchial rings, hyperoxia 
in-vivo may have effects on bronchomotor tone via neural or humoral pathways which 
could offset a direct effect of oxygen alone on airway smooth muscle responsiveness. 
The fall in heart rate associated with hyperoxia is indicative of carotid chemoreceptor 
stimulation. Airway tone may be influenced by carotid chemoreceptor activity and 
this influence may offset any protective effects that hyperoxia has on airway 
reactivity. It is also possible that the differences are explained quite simply by 
species variation. Our other studies have examined bovine bronchial rings and the 
trachea of dogs.
Our results support and extend those of Wollner et al.^ ^^  In addition to examining the 
effects of breathing 1 0 0 % oxygen on methacholine airway responsiveness we have 
also studied the potential influences of hypocapnia and circulating catecholamines on 
airway reactivity during hyperoxia. It is difficult to explain the difference in findings 
between our study and that of Inoue et a/^^ who found that breathing oxygen 
attenuated methacholine-induced bronchoconstriction in asthmatic subjects. They 
however used an inspired oxygen concentration of 30% whereas we used 100% and it 
is possible that the higher inspired oxygen concentration itself causes paradoxical 
bronchoconstriction through neural or other pathways. Review of the patients in the 
study of Inoue et al^ °^  shows differences from our own study population. None of 
their patients were receiving inhaled corticosteroids and seventeen of the thirty
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patients were on no therapy at all. More importantly however six patients had arterial 
oxygen tensions below 10 Kpa in keeping with chronic hypoxaemia. Studies have 
suggested that in patients with chronic hypoxaemia inspiring oxygen (FiOz 30%) 
causes bronchodilation^ '^^’^ ^^  and this effect may have significantly biased their 
results.
It is worth noting that in our study a small subgroup of patients with methacholine 
PC2 Q values of less than 1 .0  mg/ml on the normoxic study day derive a significant
protective effect from breathing oxygen (F iO z 1 0 0 %) against methacholine induced 
bronchoconstriction. It is interesting to speculate that attenuation of methacholine 
induced bronchoconstriction by hyperoxia in asthmatic patients may be relative to the 
degree of airway hyperresponsiveness present. In the present study we have 
examined the effect of hyperoxia on airway reactivity in a group of normoxic stable 
asthmatic patients. It is worth considering however, that in acute severe asthma 
patients are often hypoxaemic and have increased airway reactivity and it may be that 
administration of high concentrations of inspired oxygen in this group may attenuate 
airway responsiveness to bronchoconstrictor stimuli.
In conclusion these results demonstrate that breathing oxygen (F iO z 100%) in mild 
asthmatic patients does not attenuate methacholine-induced bronchoconstriction.
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Patient
No
Age
(years)
Sex FEVi
absolute 
value (L)
predicted
%
Therapy Met PC20 
mg/ml
1 36 F 2.18 81 Spm,B,TH,S 2.89
2 26 M 3.70 95 Sprn, B 0.18
3 2 1 F 2 90 103 Spm, B 1.05
4 35 F 2.28 8 6 Tprn, B 0.04
5 36 F 2 .2 0 83 Spm, B 0.77
6 30 F 2.62 94 Sprn 0 63
7 29 F 3.12 104 Spm, B 1.23
8 46 M 3.90 96 Spm 3.71
9 35 F 2.95 1 0 0 Spm, B 2 .0 0
1 0 34 F 2.40 81 Tprn, B, TH 3.9
11 45 M 2.60 87 Sprn, B 7.90
1 2 56 F 2.13 80 Spm 0.34
13 29 F 2.84 93 Sprn, B 0.41
14 43 M 3.45 81 Spm 0.19
Mean
(SD)
36
(9.2)
2.80
(0.60)
90
(8 .6 )
*0.84
Table 5.1: Patient characteristics. Met PC20 = methacholine concentration causing a 
20% fall in FEVi at an initial screening visit (* geometric mean), Spm = inhaled 
salbutamol as reqd, Tpm = inhaled terbutaline as reqd, B = inhaled steroid (budesonide 
or beclomethasone dipropionate), TH = oral theophylline, S = inhaled salmeterol twice 
daily.
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Fig 5.1 The effect o f  inhaling oxygen (FiO] 100%) and air (Fi02 21%) on 
methacholine PC20 values mg/ml in 12 mild asthmatics. (P>0.05)
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Fig 5.2 The effect o f  inhaling oxygen (FiO] 100%) and air (FiO] 21%) on oxygen  
saturation (Sa02% ), heart rate (beats per minute) and end-tidal C02% levels 
(PETC0 2 %) before, during and after a m ethacholine inhalation challenge in 12 mild 
asthmatics.
CHAPTER 6 
THE EFFECT OF ACUTE HYPOXIA ON 
METHACHOLINE INDUCED 
BRONCHOCONSTRICTION IN PATIENTS WITH
MILD ASTHMA
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6.1 Introduction
We have heard in the previous chapter how methacholine induced 
bronchoconstriction is unaffected by breathing oxygen (FiOi 1 0 0 %) in patients with 
asthma despite our in-vitro findings (chapter 5). The same in-vitro studies had also 
suggested that acute hypoxia (Fi0 2  4%) potentiated the constrictor effect of both 
methacholine^^ and endothelin-1^^ in bovine isolated bronchial rings. Several in-vivo 
studies have also suggested that acute hypoxia may potentiate histamine induced 
airway constriction in both dogs^  ^and sheep.^ '^^  ^ Few studies have examined this 
effect in patients with asthma. Denjean et af^ suggested that in patients with asthma 
airway hyperresponsiveness to methacholine was increased by hypoxia whereas Tam 
et al^ °^  showed acute hypoxia had no effect on dry air challenge in patients with 
asthma. As hypoxaemia is common in patients admitted to hospital with acute 
exacerbations of a s t h ma * ^ s u c h  an observation may have relevance in their 
emergency management. The aim of this study was to examine the effect of acute 
hypoxia (Fi0 2  15%) on methacholine induced-bronchoconstriction in patients with 
asthma.
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6.2 Patients and methods 
Patients
Eleven mild adult asthmatic patients mean (SD) age 42 (12) years were recruited into 
the study (Table 6.1). All of the patients gave a history of asthma and had an FEVi > 
80% of predicted at an initial screening visit. None of the patients had any other 
significant illnesses. All eleven patients were receiving inhaled B2 -agonists as 
required and ten patients regular inhaled corticosteroids. Two were taking inhaled 
salmeterol and a further one a long acting oral theophylline. B2-agonists were 
discontinued for 8  hours, salmeterol 24 hours and oral theophylline for 48 hours prior 
to attending for each visit. All patients gave informed consent to the study which had 
previously been approved by the West Ethics Committee.
Study design
Patients were asked to visit the laboratory on three separate study days each separated 
by one week. During the initial visit following a physical examination patients 
performed a methacholine inhalation test to determine a PC2 0  value for 
methacholine. Following thirty minutes of supine rest patients were commenced on 
our closed breathing circuit. After 10 minutes breathing air (Fi0 2  21%) baseline 
measurements of FEVi, heart rate (HR), respiratory rate (RR), oxygen saturation 
(Sa0 2 %), inspired oxygen and carbon dioxide levels (insp 0 2 %, insp CÜ2%) and 
expired oxygen and carbon dioxide levels (PET0 2 %, PETC0 2 %) were made. A 
blood sample was taken for assay of plasma catecholamines. Patients then breathed 
either air (FiOi 2 1 %) or a nitrogen and oxygen mixture (Fi0 2  15%) for the remainder 
of the study day. The measurements made at baseline were repeated 10 minutes after
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commencing the study gas. All gases were administered in a randomised double 
blind fashion by a second investigator obscured from the patients vision. After 
breathing the study gas for 1 0  minutes patients performed a methacholine inhalation 
challenge. The study day was terminated when a PC20 value for methacholine was 
obtained and a third set of measurements had been made.
Measurements
Heart rate and oxygen saturation was measured using a pulse oximetry probe (Datex 
Division of Instrumentarium Corp, Helsinki, Finland) - see chapter 2.3.
Respiratory rate, inspired and expired oxygen and carbon dioxide levels were 
measured using an OSCARoxy TM multigas monitor (Datex of Instrumentarium 
Corp, Finland, Helsinki) - see chapter 2.3.
Methacholine PC20 value (mg/ml) were measured according to the technique 
described by Cockcroft et al^ ^^  and Hargreaves et al^ ^^  -  see chapter 2.5.
FEVi was measured using a dry wedge spirometer (Vitalograph S, Vitalograph, 
Buckinghamshire, United Kingdom) - see chapter 2.2.
Plasma catecholamines were measured using reverse phase high performance liquid 
chromatography - see chapter 2 .8 .
Statistical analysis
Statistical analysis was performed using a Statview software package (Brainpower 
Inc, 24009 Ventura boulevard. Suite 250, Calabassas) on an Apple Mackintosh LCII 
computer. Paired t-tests were used to compare measurements made at each time
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point between study days. The PC2 0  values for methacholine were logarithmically 
transformed before analysis. A p value of less than 0.05 was accepted as significant.
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6.3 Results
Baseline measurements; There were no significant differences in baseline 
measurements of FEVi, heart rate, respiratory rate, oxygen saturation, end-tidal 
CÛ2%, plasma adrenaline and noradrenaline levels between the two study days.
PC2 0  value for methacholine: The geometric mean (range) PC20 value mg/ml was 
significantly lower (p<0.05) on the hypoxic day 0.89 (0.04-15.5) mg/ml than the 
normoxic day 2.45 (0.26-23.02) mg/ml (figure 6.1).
Oxygen saturation: Oxygen saturation was significantly lower on the hypoxic day 
(p<0 .0 1 ) both before and after methacholine challenge when compared to the 
normoxic day. The mean (SEM) oxygen saturation % on the normoxic day was: 
baseline 96.5 (0.16) %, pre-methacholine 96.3 (0.27) %, post-methacholine 96.0 
(0.43) %, and on the hypoxic day: baseline 96.3 (0.24) %, pre-methacholine 91.0 
(0.56) %, post-methacholine 90.5 (1.0) % (figure 6.2).
End-tidal carbon dioxide level %; End-tidal C0 2 % levels were not significantly 
different between study days. However on both study days end-tidal C0 2 % levels 
were significantly lower following methacholine challenge (p<0.05) when compared 
to baseline on both study days. The mean (SEM) end-tidal COz% on the normoxic 
day was: baseline 4.7 (0.11), pre-methacholine 4.16 (0.12), post-methacholine 3.7 
(0.19) and on the hypoxic day: baseline 4.6 (0.14), pre-methacholine 4.4 (0.18), post- 
methacholine 3.9 (0.17) (figure 6.2).
Forced expiratory volume in one second: The mean FEVi (litres) after 10 minutes 
of hypoxia alone, prior to methacholine inhalation was not significantly different 
(p>0.05) compared to the normoxic study day prior to methacholine inhalation. The
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mean FEVi (E) following 10 minutes of hypoxia alone was 2.40 (0.15) litres 
compared to 2.38 (0.14) litres on the normoxic study day.
Plasma catecholamine levels: Circulating plasma noradrenaline levels (n=l 1) on the 
normoxic study day [mean (SEM) noradrenaline nmol/1: baseline 1.70 (0.14) nmol/1, 
post-methacholine 1.60 (0.16) nmol/1] were not statistically different from the 
hypoxic study day [mean (SEM) noradrenaline nmol/1: baseline 1.61 (0.29) nmol/1, 
post-methacholine 1.40 (0.25) nmol/1]. Plasma adrenaline levels (n=l 1) on the 
normoxic study day [mean (SEM) adrenaline nmol/1: baseline 0.10 (0.02) nmol/1, 
post-methacholine 0.08 (0 .0 2 ) nmol/1] were also no different following hypoxia 
[mean (SEM) adrenaline nmol/1: baseline 0.11 (0.02) nmol/1, post-methacholine 0.06 
(0 .0 2 ) nmol/1].
Heart rate and respiratory rate: There were no significant differences in either 
heart rate (figure 6 .2 ) or respiratory rate (data not shown) between either of the study 
days at any time point.
Raw data for this chapter is included in the Appendix (tables 18A -  19A)
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6.4 Discussion
The results from this study would suggest that in patients with mild stable asthma, 
acute hypoxia potentiates methacholine induced airway bronchoconstriction.
The oxygen saturations that we have observed on the hypoxic study, day both before 
and after methacholine challenge were approximately 90%. This is in keeping with a 
moderate degree of hypoxaemia. Most patients admitted to hospital with acute 
exacerbations of asthma are hypoxaemic^^ and approximately one third with severe 
asthma have a Pa0 2  of less than 8 kPa on air.^ ’^^  ^ It would appear that our closed 
breathing circuit has managed to produce and maintain a significant level of 
hypoxaemia in our patients. We have already considered how the development of 
airway tone in man is complex and has both direct and indirect influences. During 
the design of this study, and the selection of an inspired oxygen tension of 15% we 
were acutely aware of fact that hypoxia itself might influence airway tone via a 
number of different mechanisms (chapter 4). Hypoxia has been noted to stimulate 
ventilation by an unknown mechanism. The level of hypoxia required to 
stimulate ventilation in man is however controversial. An increase in minute 
ventilation will cause a fall in end-tidal C0 2 %. Hypocapnia is associated with 
bronchoconstriction i n - v i v o In our study we have not observed any difference 
in end-tidal C0 2 % between the study days suggesting that hypocapnia has not been a 
confounding factor in our results. Airway smooth muscle tone may be influenced 
directly by the action of hypoxia on smooth muscle cells and indirectly by altered 
carotid chemoreceptor activity during hypoxaemia. In our study the FEVi on both 
study days, after breathing the study gases for 1 0  minutes but prior to commencement 
of the methacholine challenge, was not significantly different suggesting that hypoxia
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has not influenced resting airway tone in our patients. The absence of significant 
heart rate changes in our patients between the study days would suggest that the level 
of hypoxaemia we have induced has not resulted in sympathetic nervous stimulation 
which might itself have influenced resting airway tone. In our study circulating 
catecholamine levels are no different on the hypoxic and normoxic study days 
suggesting that changes in adrenaline and noradrenaline levels have not influenced 
our results.
It would appear therefore that hypoxia itself potentiates methacholine induced 
bronchoconstriction. The mechanism of this effect is unknown. Studies in sheep^^’^  ^
have suggested that alveolar hypoxia (Fi0 2  13%) increases non-specific bronchial 
reactivity to both histamine and carbachol. This effect is abolished by infusing 
cromolyn sodium, an agent which stabilises mast cell membranes^^. The authors 
concluded that mast cells might play an important role in increasing non-specific 
bronchial reactivity in sheep exposed to alveolar hypoxia. In a similar series of 
studies D’Brot and Ahmed^^ observed that inhaled FPL 57231, a leukotriene receptor 
antagonist, also attenuated increases in non-specific bronchial reactivity observed 
during alveolar hypoxia. They concluded that increased bronchial reactivity during 
alveolar hypoxia might be due to priming of airway smooth muscle by leukotrienes.
If acute hypoxia causes release of inflammatory mediators within the airways, this 
could explain why hypoxia potentiates methacholine induced bronchoconstriction in 
our patients with mild asthma. Other groups have suggested that prior surgical 
chemodenervation^^’^  ^ in animals models abolishes potentiation of methacholine and 
histamine induced bronchoconstriction by hypoxia. If this is the case and the effect is 
mediated by peripheral nerves it does not explain our own in-vitro findings where
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endothelin-1 and methacholine induced smooth muscle contractions were potentiated 
by hypoxia in bovine isolated bronchial rings deprived of their normal neural and 
humoral influences/^'^^ Hypoxia may act directly on peripheral nerves to stimulate 
neurotransmitter release or directly on smooth muscle to cause an increase in smooth 
muscle tone. These possibilities seem less likely in light of the difficulties 
researchers have had in establishing that hypoxia does indeed cause increased airway 
tone in man.
These findings may well have clinical relevance in acute exacerbations of asthma as 
hypoxia may not only occur as a consequence of airway constriction but also act to 
potentiate the airway constriction itself. In conclusion our study has suggested that 
acute hypoxia (Fi0 2 15%) potentiates methacholine induced bronchoconstriction in 
patients with mild stable asthma.
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Patient
No
Age
(years)
Sex FEVi
absolute predicted 
Value (L) %
Therapy Met PC2C 
mg/ml
1 35 F 2.83 97 Sprn, B 0.77
2 33 M 3.87 81 Spm, B 5.60
3 57 F 2.30 85 Spm, B 0.34
4 35 F 2.45 80 Sprn 0.63
5 69 M 2.58 82 Spm, B, S 1.71
6 45 M 2.72 86 Spm, B 7.90
7 30 F 3.12 104 Spm, B 1.23
8 48 M 3.17 82 Spm, B 0.35
9 42 F 2.08 80 Tpm, B,S 0.04
10 35 F 2.53 85 Spm, B, TH 3.96
11 33 M 2.78 83 Sprn, B 4.42
Mean
(SD)
42
(12)
2.76
(0.49)
86
(7.7)
*1.13
Table 6.1: Patient characteristics. Met PC20 = methacholine concentration causing a 
20% fall in FEVi at an initial screening visit (* geometric mean), Spm = inhaled 
salbutamol as reqd, Tprn = inhaled terbutaline as reqd, B = inhaled steroid 
(budesonide or beclomethasone dipropionate), TH = oral theophylline, S = inhaled 
salmeterol twice daily.
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Fig 6.1 The effect of inhaling oxygen (FiOi 15%) and air (FiO] 21%) on 
methacholine PC20 values mg/ml in 11 mild asthmatics. (P<0.05)
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Fig 6.2 The effect of inhaling oxygen (FiO] 15%) and air (FiO] 21%) on oxygen 
saturation (Sa02%), heart rate (beats per minute) and end-tidal €0]%  levels 
(PETC02%) before, during and after methacholine inhalation challenge in 11 mild 
asthmatics.
CHAPTER 7 
THE EFFECT OF ACUTE ALTERATIONS IN 
INSPIRED OXYGEN TENSION ON HISTAMINE 
INDUCED BRONCHOCONSTRICTION IN 
PATIENTS WITH MILD ASTHMA
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7.1 Introduction
We already know that in-vitro results from our own laboratory have suggested that 
acute alterations in ambient oxygen tension may have significant effects on airway 
smooth muscle responses to constrictor stimuli/^'^^ In bovine isolated bronchial rings 
hypoxia potentiates and hyperoxia attenuates airway smooth muscle constriction to 
methacholine/^ Paradoxically however in human isolated bronchial rings hypoxia 
attenuates the contractile response to both methacholine and histamine (chapter 3). 
In-vivo studies in sheep have also suggested that hypoxia potentiates histamine 
induced bronchoconstriction/^’^  ^ From our own studies described in chapters 5 and 6 
airway hyperresponsiveness to methacholine, in patients with asthma, is potentiated 
by hypoxia and unaffected by hyperoxia. It is not however known if the effects we 
have described are specific to methacholine or if changes in airway oxygen tension 
alter airway responsiveness in-vivo to other constrictor stimuli. As we have 
previously suggested such observations may have relevance to the management of 
patients with acute exacerbations of asthma. The present study was designed to 
examine the effect of acute alterations in inspired oxygen tension on airway 
responsiveness to histamine in-vivo in patients with mild stable asthma.
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7.2 Subjects and methods 
Subjects
Fourteen mild asthmatic patients (8 female) with a mean SD age of 39 (13) years 
were recruited into the study (table 7.1). All patients had a history of asthma and a 
FEVi > 80% of predicted at an initial screening visit. None of the patients gave a 
history of any other significant cardiac or respiratory illness. The patients were all 
receiving inhaled B2-agonists as required. 12 of the patients were also taking regular 
inhaled corticosteroids and of these 2 were also receiving the long acting B2-agonist 
salmeterol. All of the patients gave written informed consent to the study and the 
protocol had the approval of the West Ethical Committee.
Study design
Patients were asked to attend the laboratory on four separate study days at 
approximately the same time each day. Inhaled B2-agonists were discontinued for 8 
hours and salmeterol for 24 hours prior to attendance at the laboratory. Patients were 
asked to continue their inhaled corticosteroids as normal. At an initial screening visit 
patients underwent a full physical examination, performed baseline spirometry and 
then undertook a histamine inhalation challenge test to determine a PC20 value for 
histamine; ie that concentration of histamine causing a 20% fall in FEVi. Those with 
a PC20 value of less than 8 mg/ml were deemed eligible for the remaining 3 study 
days.
On three subsequent study days on arrival patients were asked to rest supine for 30 
minutes. They were then commenced on the closed breathing circuit already 
described -  chapter 2.6. Following a ten minute run in period breathing air (Fi02
1 0 1
21%) baseline measurements of FEVi, heart rate (HR), respiratory rate (RR), oxygen 
saturation (SaÛ2%), end-tidal carbon dioxide and oxygen levels (PETC02%, 
PET0 2 %) and inspired carbon dioxide and oxygen levels (insp C0 2 %, insp 0 2 %) 
were made. Patients then received the study gas, air (Fi02 21%), hyperoxia (Fi02 
100%) or a hypoxic gas mixture (Fi02 15%) for the remainder of that study day. All 
of the study gases were administered in a randomised double blind fashion by a 
second operator obscured from the vision of both the patient and the doctor 
performing the histamine inhalation challenge. 10 minutes after commencing the 
study the measurements made at baseline were repeated and the histamine test was 
performed. The study day was terminated when a PC20 value had been obtained and 
the measurements made at baseline had been repeated.
Measurements
Heart rate and oxygen saturation was measured using a pulse oximetry probe (Datex 
Division of Instrumentarium Corp, Helsinki, Finland) - see chapter 2.3.
Respiratory rate, inspired and expired oxygen and carbon dioxide levels were 
measured using an OSCARoxy TM multigas monitor (Datex of Instrumentarium 
Corp, Finland, Helsinki) - see chapter 2.3.
Histamine PC20 value (mg/ml) was measured according to the technique described by 
Cockcroft et a/^^ and Hargreaves et al^ ^^  -  see chapter 2.5.
FEVi was measured using a dry wedge spirometer (Vitalograph S, Vitalograph, 
Buckinghamshire, United Kingdom) - see chapter 2.2.
1 0 2
Statistical analysis
Statistical analysis was performed using a Statview software package (Brainpower 
Inc, 24009 Ventura Boulevard, Suite 250, Calabassas) on an Apple Mackintosh LC II 
computer. Analysis of variance (ANOVA) corrected for multiple comparisons were 
used to compare measurements between study days. The PC20 values were 
logarithmically transformed before analysis using paired t-tests. A p-value below 
0.05 was accepted as significant.
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7.3 Results
Baseline measurements: There were no significant differences in baseline 
measurements of FEVi, heart rate, respiratory rate, oxygen saturation and end-tidal 
C0 2 % between the three study days.
Histamine PC20 values: There was no significant difference (p>0.05) in the mean 
histamine PC20 values mg/ml between the three study days. The mean (range) PC20 
values mg/ml on each study day were: hypoxia study day 1.91 (0.27-27.4) mg/ml, 
normoxia study day 2.19 (0.3-15.4) mg/ml and hyperoxia study day 2.32 (0.29-19.0) 
mg/ml (figure 7.1).
FEVi: There were no significant differences in FEVi values (p>0.05) between the 
study days 10 minutes after commencing the study gas prior to inhalation of 
histamine. The mean (SEM) FEVi value litres 10 minutes after commencing the 
study gas on each day was: hypoxia study day 2.65 (0.18) litres, normoxia study day 
2.73 (0.16) litres and hyperoxia study day 2.65 (0.18) litres.
Oxygen saturation: Oxygen saturation was significantly higher (p<0.01) on the 
hyperoxic study day when compared to the normoxic and hypoxic study days both 
before and after histamine inhalation. Oxygen saturation was significantly lower 
(p<0.01) on the hypoxic study day when compared to the normoxic study day both 
before and after histamine inhalation. The mean (SEM) oxygen saturation % on 
completion of each study day was: hypoxia study day 89 (0.9)%, normoxia study day 
96 (0.3)% and hyperoxia study day 98 (0.2)% (figure 7.2).
Heart rate: Heart rate was significantly lower (p<0.01) on the hyperoxic study day 
when compared to both the normoxic and hypoxic study days both before and after 
inhalation of histamine. The mean (SEM) heart rate (bpm) on each study day at 
baseline, prior to histamine inhalation and after histamine inhalation was: hypoxia
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study day 71 (3) bpm, 74 (3) bpm and 72 (3) bpm: normoxia study day 71 (4) bpm, 71 
(4) bpm and 74 (4) bpm: hyperoxia study day 71 (3) bpm, 66 (3) bpm and 68 (3) bpm. 
There were no significant differences in heart rate (p>0.05) at any time point between 
the hypoxic and normoxic study days (figure 7.2).
End-tidal €0%%: There were no significant differences in the end-tidal C02% levels 
between the three study days at any time point. The mean (SEM) end-tidal C02% 
levels on each study day following inhalation of histamine were: hypoxia study day 
3.8 (0.2)%, normoxia study day 4.2 (0.2)% and hyperoxia study day 4.0 (0.1)% (figure 
7.2).
Respiratory rate: There were no significant differences in the respiratory rates at any 
time point between any of the three study days (data not shown).
Raw data for this chapter is included in the Appendix (tables 20A -  21A)
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7.4 Discussion
In the two previous chapters we have demonstrated that hypoxia potentiates and 
hyperoxia has no effect on methacholine induced bronchoconstriction in patients with 
stable asthma. In the current study both hypoxia and hyperoxia had no effect on 
histamine induced bronchoconstriction in a similar group of patients.
The rise in oxygen saturation and fall in heart rate seen on the hyperoxic study day 
and the fall in saturation on the hypoxic study day indicate that our closed breathing 
circuit has once again achieved the required changes in airway and arterial oxygen 
tension we have anticipated. The absence of a significant rise in heart rate on 
the hypoxic study day suggests that the level of hypoxia we have produced has not 
resulted in an increase in resting sympathetic tone. An increase in sympathetic 
activity may have indirect effects on airway tone which could offset the effect of 
hypoxia alone. However once again hyperoxia has induced a fall in heart rate 
suggesting reduced tonic activity of carotid chemoreceptors which may have indirect 
effects on airway tone hence influencing our results. In this study we have not 
observed any significant difference in end-tidal carbon dioxide levels between study 
days either before or after inhalation of histamine suggesting that hypocapnic 
bronchoconstriction has not influenced our results. The nebuliser output which 
had been checked prior to the study for all of the study gases used and was found to 
be 0.13 mls/min at a flow rate of 7 litres/min.
These results differ from our own in-vitro findings in human isolated bronchial rings 
where we found that hypoxia attenuated histamine induced smooth muscle 
constriction (chapter 3). This finding is in keeping with the results of several other
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similar studies/^’^ ’^^ ’^^  ^ In the absence of circulating humoral factors and neural 
innervation it seems likely that the profoundly low oxygen tension (4%) which was 
used in-vitro has acted directly on smooth muscle causing impairment of the 
contractile processes. It is not possible to use such low inspired oxygen tensions in 
our own in-vivo studies. Previous studies have shown that hypoxia impairs the 
contractile strength of airway smooth muscle/^’^  ^possibly by impairing the cells 
ability to generate ATP or by inhibiting the entry of extracellular calcium into smooth 
muscle cells. It seems likely that this effect does not occur at higher ambient 
oxygen tensions similar to those used in our in-vivo studies. It is also worth noting 
that our human bronchial rings are largely from elderly smokers undergoing elective 
thoracotomy for pulmonary malignancies rather than young fit asthmatic patients.
This observation may also account for some of the differences between our in-vitro 
and in-vivo studies.
Our study has shown no change in airway hyperresponsiveness to histamine at various 
inspired oxygen tensions in patients with asthma. This contrasts with the findings of 
Vidruk and Sorkness^^ who found hypoxia potentiated and hyperoxia attenuated 
histamine induced tracheal constriction in mongrel dogs. It is worth noting that they 
used an inspired oxygen tension of 12% and that the animals in his studies had been 
anaesthetised. The anaesthetic drugs in combination with the altered oxygen tensions 
used may have effects on circulating humoral factors or chemoreceptor activity which 
have influenced their results. Our study results also differ from those of D’Brot and 
Ahmed^^ who using conscious sheep also demonstrated potentiation of histamine 
induced bronchoconstriction by hypoxia. The prevailing pattern of histamine 
receptors detennines the effect of histamine on airway smooth muscle. Since it varies
107
considerably between species and even between different sites in the same airway/ 
extrapolation of results from animal models to man has created considerable 
confusion. It is possible therefore that differences between the animal studies and our 
own can be explained by species variation alone.
Our findings also differ from the results of our own previous study in which we 
demonstrated that hypoxia potentiates methacholine induced bronchoconstriction in 
patients with mild asthma. This difference has occurred despite using the same 
inspired oxygen tension, study design and breathing circuit in both studies. This is an 
intriguing observation that is difficult to account for. Both methacholine and 
histamine interact with specific receptors on airway smooth muscle cells. This 
interaction results in the production of inositol phospholipid metabolites via a 
complex biochemical pathway. Inositol 1,4,5 triphosphate, an intracellular second 
messenger, causes release of intracellular calcium ions which promotes smooth 
muscle contraction. One could speculate that hypoxia has a specific effect on 
acetylcholine receptors which when methacholine binds to them augments smooth 
muscle contraction, perhaps via an effect on regulatory G-proteins. Hypoxia (Fi02 
15%) does not seem to have the same effect on histamine receptors in-vivo in patients 
with mild asthma.
In conclusion we have shown that acute alterations in inspired oxygen tension do not 
alter histamine induced bronchoconstriction in patients with stable asthma.
Patient
No
Age
(years)
Sex FEVi 
absolute predicted
Therapy
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PC20 histamine 
(mg/ml)
1 21 F 2.94 97 Spm, B 1.18
2 28 F 2.84 93 Spm, B 0.41
3 69 M 2.61 88 Spm, B 1.31
4 41 F 2.90 116 Spm, B 2.00
5 42 F 2.27 88 Tpm, B, S 5.86
6 31 F 2.27 80 Spm 2.98
7 57 F 2.19 83 Spm, B 1.81
8 48 M 3.24 83 Sprn 1.27
9 29 M 4.20 87 Spm, B 2.65
10 33 M 4.28 81 Spm, B 3.03
11 35 F 2.59 92 Spm, B, S 3.46
12 32 M 3.84 85 Spm, B 0.29
13 34 M 4.14 91 Sprn, B 6.80
14 46 F 2.30 97 Spm, B 1.27
Mean 39 3.04 91 *1.79
(SD) (12.8) (0.77) (9.2)
Table 7.1: Patient characteristics. Histamine PC20 = histamine concentration causing 
a 20% fall in FEVi at an initial screening visit (* geometric mean) Spm = inhaled 
salbutamol as reqd, Tpm = inhaled terbutaline as reqd, B = inhaled steroid 
(budesonide or beclomethasone dipropionate), S = inhaled salmeterol twice daily.
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Fig 7.1 The effect of inhaling oxygen (Fi0215%, 21% and 100%) histamine PC20 
values mg/ml in 14 mild asthmatics. (P>0.05)
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Fig 7.2 The effect of inhaling oxygen (FiOz 15%, 21% and 100%) on oxygen 
saturation (Sa0 2 %), heart rate (beats per minute) and end-tidal C0 2 % levels 
(PETC02%) before, during and after a histamine inhalation challenge in 14 mild 
asthmatics.
CHAPTER 8 
THE EFFECT OF ACUTE HYPEROXIA ON THE 
BRONCHODILATOR RESPONSE TO 
SALBUTAMOL IN PATIENTS WITH ASTHMA
I l l
8.1 Introduction
We have focussed, in the last three chapters, on the effect of acute alterations in 
inspired oxygen tension on bronchoconstrictor responses in patients with asthma. Our 
own in-vitro studies on isolated bronchial rings had also suggested that acute 
alterations in ambient oxygen tension had effects on airway responses to 
bronchodilator stimuli. In bovine isolated bronchial rings hyperoxia (O2 95%) 
potentiates salbutamol induced smooth muscle relaxation in rings preconstricted with 
methacholine.^^ In human isolated bronchial rings hypoxia attenuates the 
bronchodilator response to salbutamol whereas hyperoxia has no effect on salbutamol 
induced smooth muscle relaxation when compared to normoxia (chapter 3). It has 
previously been shown that in-vivo hyperoxia attenuates exercise induced 
bronchoconstriction in patients with asthma. No previous studies, to our 
knowledge, have investigated the effect of acute hyperoxia on bronchodilator 
responses in patients vnth asthma. If acute hyperoxia can alter the airway response to 
bronchodilators such as salbutamol then the administration of high inspired oxygen 
concentrations during acute exacerbations of asthma may not only improve gas 
exchange but could also enhance the effects of both nebulised and intravenous 
bronchodilators which are administered. The present study was designed to examine 
the effect of breathing 100% oxygen on the bronchodilator response to salbutamol in 
patients with stable asthma.
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8.2 Subjects and methods 
Subjects
Twelve adult asthmatic patients (three female) with a mean (SD) age of 47 (14) were 
recruited into the study (table 8 .1). All of the patients had a diagnosis of asthma and 
no patient had a history of any other significant cardiac or respiratory illness. All of 
the patients were taking inhaled Bi-agonists as required and 11 regular inhaled 
corticosteroids. Two were also receiving the long acting B2-agonist salmeterol and 2 
had been provided with a home nebuliser to take salbutamol on an as required basis. 
One patient was receiving a short acting oral theophylline. The research was carried 
out in accordance with the Declaration of Helsinki (1989) and all of the patients gave 
written informed consent to the study protocol which had the approval of the West 
Ethics Committee.
Study design
Patients were asked to attend the laboratory on five separate days at approximately 
the same time on each day. Prior to each day patients were required to withhold all 
inhaled B2-agonists for 8 hours, long acting B2-agonists such as salmeterol for 24 
hours and oral theophyllines for 48 hours. They were asked to continue their normal 
inhaled corticosteroids as usual. At an initial screening visit patients had their FEVi 
measured before and after inhaling 5mg of nebulised salbutamol. Those patients who 
demonstrated a 15% rise in FEVi following nebulised salbutamol were deemed 
eligible for the remaining four study days.
On four subsequent study days after 30 minutes of supine rest patients were 
commenced on the closed breathing circuit already described -  chapter 2.6.
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Following a ten minute run-in period during which patients breathed air (Fi02 21%) 
baseline measurements of FEV], oxygen saturation (Sa02%), respiratory rate (RR), 
heart rate (HR), inspired oxygen and carbon dioxide levels (insp 02%, insp 002%) 
and expired oxygen and carbon dioxide levels (PET 02%, PET 002%) were made. 
Venous blood was also taken for assay of plasma catecholamines. Patients were then 
randomised to inhale either air (Fi0 2  21%) on two study days or oxygen (F1O2 100%) 
on the remaining two study days, The study gases were administered in a randomised 
double blind fashion by an observer hidden from the view of both the subject and the 
operator. After 10 minutes breathing the study gas through the closed breathing 
circuit the patients received either three incremental concentrations of nebulised 
salbutamol (0.05 mg/ml, 0.17 mg/ml, 5 mg/ml) or placebo (normal saline) at 15 
minute intervals again in a double blind fashion. Nebulised salbutamol was given 
through a micro cirrus nebuliser (Intersurgical Ltd, Orane House, Wokingham, 
Berkshire) for 2 minutes driven by either the hyperoxic or normoxic study gas at a 
flow rate of 7 L/min to produce a nebuliser output of 0.13 mls/min. Baseline 
measurements were repeated thirteen minutes after each nébulisation until 
completion of the study day.
Measurements
Heart rate and oxygen saturation were measured using a pulse oximetry probe (Datex 
Division of Instrumentarium Oorp, Helsinki, Finland) - see chapter 2.3.
Respiratory rate, inspired and expired oxygen and carbon dioxide levels were 
measured using an OSOARoxy TM multigas monitor (Datex of Instrumentarium 
Oorp, Finland, Helsinki) - see chapter 2.3.
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FEVi was measured using a dry wedge spirometer (Vitalograph S, Vitalograph, 
Buckinghamshire, United Kingdom) - see chapter 2.2.
Plasma catecholamines were measured using reverse phase high performance liquid 
chromatography - see chapter 2.8.
Statistical analysis
Statistical analysis was performed using a Statview software package (Brainpower 
Inc, 24009 Ventura Boulevard, Suite 250, Calabassas) on an Apple Mackintosh LCII 
computer. Analysis of variance (ANOVA) corrected for multiple comparisons was 
used to compare measurements made at baseline and following each dose of 
nebulised saline or salbutamol between study days. A p value of <0.05 was 
considered significant.
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8.3 Results
Baseline measurements: There were no significant differences in baseline 
measurements of heart rate, respiratory rate, oxygen saturation, FEVi and end-tidal 
C0 2 % between the four study days.
Absolute change in FEVi from baseline: There was no significant difference 
(p>0.05) in the mean change in FEVi (litres) from baseline after breathing the study 
gas for 10 minutes, but before administration of nebulised salbutamol or placebo on 
any study day. The mean (SEM) change in FEVi (litres) from baseline on each study 
day was: hyperoxia/salbutamol study day -0.08 (0.05) litres, normoxia/salbutamol 
study day -  0.06 (0.09) litres, hyperoxia/placebo study day 0.01 (0.05) litres and 
normoxia/placebo study day 0.05 (0.07) litres. There was no significant difference in 
the mean maximum change in FEVi (Litres) from baseline after nebulised salbutamol 
on the normoxic and hyperoxic study days. The mean maximum change in FEVi 
from baseline was significantly greater (p<0.01) on the days on which nebulised 
salbutamol was administered when compared to placebo (nebulised saline). The 
mean maximum (SEM) change in FEVi (litres) from baseline was on the: 
hyperoxia/salbutamol study day 0.37 (0.08) litres, normoxia/salbutamol study day 
0.36 (0.05) litres, hyperoxia/placebo study day -0.04 (0.08) litres and 
normoxia/placebo study day-0.08 (O.IO) litres (figure 8.1).
Oxygen saturation: Oxygen saturation was significantly greater (p < 0.01) on both 
hyperoxic study days at 15, 30 and 45 minutes when compared to the normoxic study 
days. The mean (SEM) oxygen saturation % at 45 minutes on each study day was 
hyperoxia/salbutamol study day 98 (0.5) %, normoxia/salbutamol study day 96 (0.5) 
%, hyperoxia/placebo study day 98 (0.5) % and normoxia/placebo study day 96 (0.5) 
% (figure 8.2).
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Heart rate: The mean maximum fall in heart rate from baseline was significantly 
greater (p < 0.05) at 15, 30 and 45 minutes on the study days on which the high 
inspired oxygen tension was administered to the subjects. The mean (SEM) fall in 
heart rate (bpm) from baseline following completion of each study day was: 
hyperoxia/salbutamol study day -5.2 (1.3) beats per minute, normoxia/salbutamol 
study day -2.1 (1.3) beats per minute, hyperoxia/placebo study day -4.6 (1.9) beats 
per minute and normoxia/placebo study day -3.1 (0.7) beats per minute (figure 8.1). 
End-tidal €0%%: The mean (SEM) end-tidal 00%% was significantly lower (p < 
0.05) on the hyperoxia/placebo study day when compared to the normoxia/placebo 
day at 45 minutes only. There were no other time points between study days that end- 
tidal C02% levels were significantly different. End-tidal C02% levels were similar at 
all time points on the study days on which salbutamol was administered. The mean 
(SEM) end-tidal C02% levels at 45 minutes on each study day were: 
hyperoxia/salbutamol study day 4.2 (0.19)%, normoxia/salbutamol study day 4.1 
(0.25)%, hyperoxia/placebo study day 3.9 (0.2)% and normoxia/placebo study day 4.2 
(0.2)% (figure 8.2).
Plasma catecholamine levels: There were no significant differences in circulating 
catecholamine levels at 15, 30 and 45 minutes between the study days (p>0.05). The 
mean (SEM) circulating adrenaline levels at 45 minutes on each study day were: 
hyperoxia/salbutamol study day 0.11 (0.02) nmol/1, normoxia/salbutamol study day 
0.19 (0.03) nmol/1, hyperoxia/placebo study day 0.07 (0.02) mnol/1 and 
normoxia/placebo study day 0.09 (0.02) nmol/1. The mean (SEM) circulating 
noradrenaline levels at 45 minutes on each study day were: hyperoxia/salbutamol 
study day 2.11 (0.39) nmol/1, normoxia/salbutamol study day 2.81 (0.77) nmol/1,
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hyperoxia/placebo study day 2.22 (0.37) ninol/l and normoxia/placebo study day 1.91 
(0.41) nmol/1.
Respiratory rate: There was no significant differences in respiratory rate (breaths 
per minute) at 10, 15, 30 and 45 minutes between any of the study days (data not 
shown).
Raw data for this chapter is included in the Appendix (tables 22A -  26A)
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8.4 Discussion
The results from our study have confirmed that acute hyperoxia (Fi02 100%) has no 
effect on the bronchodilator response to salbutamol in patients with stable asthma.
We have observed in our patients a significant rise in oxygen saturation and fall in 
heart rate on the hyperoxic study days when compared to the normoxic study 
days.^ ^^ '^ ^^  These observations would suggest that once again our closed breathing 
circuit has achieved a high arterial oxygen tension. Airway oxygen tension will be 
similar to that of the inspired gas, in this case 100%. These changes in arterial and 
airway oxygen tensions should have allowed appropriate testing of our hypothesis.
The possibility of hyperoxia causing an increase in minute ventilation by an indirect 
action on either the brainstem or peripheral chemoreceptors was raised as a possible 
confounding variable in our s t u d y . A n  increase in minute ventilation causes 
hypocapnia which is known to cause increased airway tone.^ *^^ '^ ^^  A fall in end-tidal 
C02% would be expected to accompany any increase in minute ventilation. In this 
study we have observed a significant fall in end-tidal C02% at 45 minutes on the 
hyperoxia/placebo day compared with the other days. This observation raises the 
possibility that in our study breathing 100% oxygen has caused mild hypocapnia 
which has increased airway tone and opposed any beneficial effects of hyperoxia 
alone on salbutamol induced bronchodilation in our patients. It is worth noting 
however that in our study no difference was observed, in end tidal CÛ2% levels, 
between the hyperoxia/salbutamol and normoxia/salbutamol study days suggesting 
that this is unlikely. We have in our study used the fall in heart rate from baseline as 
a surrogate marker of raised arterial oxygen tension in our patients. The fall
in heart rate that accompanies hyperoxia has been attributed to a reduction in tonic
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activity in carotid chemoreceptors.*^^ The influence of carotid chemoreceptors on 
airway tone remains controversial and poorly understood. It is possible that 
alterations in carotid and peripheral chemoreceptors tonic activity has had influences 
on airway tone in our patients which have obscured any direct effect of hyperoxia on 
salbutamol induced airway relaxation. Circulating catecholamines have influences 
on airway tone in-vivo in patients with asthma.^ "* There was however no significant 
difference in plasma adrenaline and noradrenaline levels between any of our study 
days at any time point suggesting that their levels have not influenced our results in 
this study. As in the other studies the nebuliser output was found to be 0.13 mls/min 
at a flow rate of 7 litres/min for oxygen (FiO^ 100%) and air (FiOi 21%).
Once again we are left with significant differences between our in-vitro findings in 
bovine^^’^  ^and human isolated bronchial rings and our in-vivo clinical findings in 
patients with asthma (chapter 3). While species variation may explain the differences 
in findings from our in-vitro studies on bovine bronchial rings it certainly does not 
account for the differences in human rings. It is worth noting that our human 
bronchial rings came mainly from patients undergoing elective thoracotomy for 
resection of lung cancer. These are predominantly elderly patients with a smoking 
related lung condition. As such their airways may well be significantly different from 
those of a younger patient with asthma. It is more likely that hyperoxia has an 
indirect effect on airway tone via unrecognised neural or humoral pathways. The 
most striking difference between our in-vitro and in-vivo studies, using high oxygen 
tensions, is the absence of neural innervation and circulating humoral factors in our 
bronchial rings. Against this hypothesis is the absence of change in FEVi that we 
have found in our patients breathing 100% oxygen for 10 minutes before receiving
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nebulised salbutamol or placebo. This would suggest that breathing oxygen has not 
had a direct effect on resting airway tone in our patients.
It has been suggested from in-vitro studies that the density of B2-receptors on cell 
membranes may be influenced by the ambient oxygen t e n s i o n . A  reduction in 
ambient oxygen tension may reduce (^ 2-receptor density and conversely hyperoxia 
may increase receptor numbers. It is not clear however how long alterations in 
receptor density take following a change in ambient oxygen tension. Our study has 
only examined the effect of hyperoxia on salbutamol induced relaxation over 60 
minutes. It is possible that any change p2 receptor density takes longer than this to 
develop. Such an observation may have influenced our results.
We conclude from our study that breathing 100% oxygen for a period of 60 minutes 
has no effect on salbutamol induced bronchodilation in patients with stable asthma.
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FEVi
Patient
No
Age
(years)
Sex absolute value (L) 
pre-sal post-sal
post-sal 
% predicted
Current
treatment
1 46 F 1.55 2.01 84 sal pm, B
2 48 M 2.54 3.38 94 sal pm, B, S, TH
3 55 M 1.84 3.08 75 sal pm, B
4 69 M 2.18 2.69 81 sal pm, B
5 41 M 2.50 2.97 76 sal pm, B
6 42 M 2.18 3.14 90 sal pm,B
7 61 M 1.04 1.37 40 sal pm, B, P, Neb
8 34 F 2.28 2.87 104 T pm, B
9 40 M 1.45 2.45 77 sal pm, B, P, Neb
10 26 F 1.89 2.31 72 sal pm, B, S
11 70 M 1.81 2.21 64 sal pm, B
12 39 M 3.33 3.87 96 sal pm
Mean
(SD)
47
(14)
2.05
(0.60)
2.70
(0.67)
79
(17)
Table 8.1: Patient characteristics, sal pm = inhaled salbutamol as required, T pm = 
inhaled terbutaline as required, B = inhaled steroid (beclomethasone or budesonide),
P = oral prednisilone, S = inhaled salmeterol twice daily, Th = oral theophylline, Neb 
= nebulised salbutamol and ipratropium bromide as required, pre-sal = pre-salbutamol 
FEV], post-sal = post-salbutamol FEVi.
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Fig 8.1 The effect of 3 incremental doses of nebulised salbutamol or placebo on absolute 
change in FEVi and heart rate from baseline whilst breathing air (FiOz 21%) or oxygen 
(FiOz 100%) in twelve asthmatic patients.
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Fig 8.2 The effect of 3 incremental doses of nebulised salbutamol or placebo on oxygen 
saturation (Sa02%) and end-tidal COz% levels (PETC02%) breathing air (Fi02 21%) or 
oxygen (Fi0 2  100%) in twelve asthmatic patients.
CHAPTER 9 
THE EFFECT OF ACUTE ALTERATIONS IN 
INSPIRED OXYGEN TENSION ON THE 
BRONCHODILATOR RESPONSE TO 
SALBUTAMOL IN PATIENTS WITH ASTHMA
124
9.1 Introduction
In-vitro studies have suggested that acute alterations in ambient oxygen tension may 
significantly alter the effect of bronchodilator stimuli on airway smooth muscle tone/^'^^ 
We have found in our own laboratory that in bovine isolated bronchial rings, reversal of 
methacholine-induced tone by the bronchodilator salbutamol is significantly enhanced by 
hyperoxia and attenuated by hypoxia/^ In-vitro studies described in chapter 3, also from 
our own laboratory have suggested that in human isolated bronchial rings acute hypoxia 
significantly reduces the ability of the bronchodilator salbutamol to reverse methacholine 
induced airway tone. Such observations may have particular relevance to the 
management of acute exacerbations of asthma where patients admitted to hospital are 
often hypoxaemic.^^’^ ’^^  ^ In the previous chapter we have suggested that breathing 100% 
oxygen has no effect on salbutamol induced relaxation of airway smooth muscle in 
patients with stable asthma. The effect of acute hypoxia on airway smooth muscle 
relaxation in patients with asthma has not to our knowledge been previously examined. 
The present study was designed to examine the effect of acute hypoxia on salbutamol 
induced bronchodilation in patients with asthma.
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9.2 Methods 
Subjects
Twelve adult asthmatic patients (2 female) with a mean (SD) age 39 (8) years agreed to 
participate in the study (table 9.1). All of the patients gave a history of asthma and none 
had any other significant cardiac or respiratory disease. All of the patients were taking 
inhaled Bz-agonists as required and eleven regular inhaled corticosteroids. Three were 
also receiving the long acting B^-agonist salmeterol and one had been provided with a 
home nebuliser to take salbutamol on an as required basis. One patient was receiving a 
short acting oral theophylline. The research was carried out in accordance with the 
Declaration of Helsinki (1989) and all of the patients gave written informed consent to 
the study protocol which had the approval of the West Ethics Committee.
Study design
Patients were asked to attend the study laboratory on five separate days at approximately 
the same time each day. Prior to each study day patients were asked to withhold their 
inhaled and nebulised B2-agonists for 8 hours and inhaled salmeterol for 24 hours. Oral 
theophyllines were discontinued 48 hours prior to each study day. Patients were asked to 
continue taking their inhaled corticosteroids as usual. Patients who at an initial visit, 
following 30 minutes of supine rest, demonstrated an improvement in FEVi of more than 
15% following the administration of 5mg of nebulised salbutamol were deemed eligible 
for the remaining four study days.
On subsequent study days after arrival at the laboratory patients were asked to rest in a 
supine position for 30 minutes following which they were connected to a closed breathing 
circuit for the delivery of all study gases. After breathing air (Fi02 21%) for 10 minutes
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through the closed breathing circuit, baseline measurements of oxygen saturation 
(Sa02%), heart rate (HR), respiratory rate (RR), inspired oxygen and carbon dioxide 
levels (insp 0 2 %, insp C0 2 %) and end-tidal oxygen and carbon dioxide levels (PET0 2 %, 
PETC0 2 %) were made.
After the baseline measurements had been recorded patients were then randomised, in a 
double blind fashion, to breathe either a hypoxic gas mixture (Fi0 2 15%) on two days or 
oxygen (Fi02 100%) on two further study days for the remainder of that day. Ten minutes 
after commencing the study gas for that day the measurements made at baseline were 
repeated. Subsequently at fifteen minute intervals in a randomised double blind fashion 
patients received either three incremental doses of nebulised salbutamol (0.05 mg/ml, 
0.17 mg/ml, 5 mg/ml) on two days or placebo (nebulised saline) on two further days. 
Measurements were repeated thirteen minutes after each nébulisation until completion of 
the study day. Each dose of salbutamol or saline was given through a micro cirrus 
nebuliser (Intersurgical Ltd, Crane House, Wokingham, Berkshire) for two minutes 
driven by a hypoxic gas mixture (British Oxygen Corporation, Special Gases Division, 
Manchester) or oxygen (FiÜ2 100%) at a rate of 6 litres/min to produce a nebuliser output 
of 0.11 mls/min.
Measurements
Heart rate and oxygen saturation were measured using a pulse oximetry probe (Datex 
Division of Instrumentarium Corp, Helsinki, Finland) - see chapter 2.3.
Respiratory rate, inspired and expired oxygen and carbon dioxide levels were 
measured using an OSCARoxy TM multigas monitor (Datex of Instrumentarium 
Corp, Finland, Helsinki) - see chapter 2.3.
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FEVi was measured using a dry wedge spirometer (Vitalograph S, Vitalograph, 
Buckinghamshire, United Kingdom) - see chapter 2.2.
Statistical analysis
Statistical analysis was performed using a Statview software package (Brainpower 
Inc, 24009 Ventura Boulevard, Suite 250, Calabassas) on an Apple Mackintosh LC II 
computer. Analysis of variance (ANOVA) corrected for multiple comparisons was 
used to compare measurements made at baseline and following each dose of 
nebulised saline or salbutamol between study days. A p value of <0.05 was 
considered significant.
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9.3 Results
Baseline measurements: There were no significant differences in the baseline 
measurements of FEVi, heart rate, respiratory rate, oxygen saturation, end-tidal 00%% 
made between any of the study days.
Absolute change in FEVi from baseline: The mean (SEM) maximum change in 
FEVi from baseline was significantly greater (p<0.05) on the days on which nebulised 
salbutamol was administered: hyperoxia/salbutamol 0.49 (0.11) litres, 
hypoxia/salbutamol 0.40 (0.09) litres when compared to the study days on which 
nebulised saline was administered: hyperoxia/placebo -0.013 (0.05) litres, 
hypoxia/placebo -0.074 (0.079) litres (figure 9.1). There was however no significant 
difference in the mean maximum change in FEVi (litres) from baseline at any time 
point between the study days on which nebulised salbutamol was given. There was no 
significant difference in the mean % change in FEVi from baseline on any study day 
10 minutes after being commenced on the study gas for that day but prior to 
inhalation of nebulised salbutamol or saline. The mean (SEM) % change in FEVi 
from baseline 10 minutes after commencing each study gas was: 
hyperoxia/salbutamol-0.03 (3.5) %, hypoxia/salbutamol-0.02 (3.6) %, 
hyperoxia/placebo 0.04 (2.1) % and hypoxia/placebo 0.03 (2.5) %.
Oxygen saturation: Oxygen saturation was significantly higher (p<0.01) on the days 
on which the hyperoxic gas mixture was administered when compared to the days on 
which the hypoxic gas mixture was inhaled at all time points. The mean (SEM) 
oxygen saturation % at the completion of each study day was: hyperoxia/salbutamol 
study day 98 (0.24)%, hypoxia/salbutamol study day 87 (0.92)%, hyperoxia/placebo 
study day 98 (0.26)% and hypoxia/placebo study day 88 (0.84)% (figure 9.2).
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Heart rate: The fall in heart rate from baseline was significantly greater (p<0.01) on 
the days that patients inhaled the hyperoxic gas mixture when compared to the days 
on which they inhaled the hypoxic gas mixture at all time points. The mean (SEM) 
fall in heart rate from baseline (beats per minute) at 15, 30 and 45 minutes on each 
study day was: hyperoxia/salbutamol study day -4  (2) bpm, -4 (2) bpm, -6(1) bpm: 
hypoxia/salbutamol study day 2(1) bpm, -1(1) bpm, 1 (2) bpm: hyperoxia/placebo 
study day -6(1) bpm, -8(1) bpm, -10 (2) bpm: hypoxia/placebo study day 3 (2) bpm, 
2 (1) bpm, 1 (2) bpm (figure 9.1).
End-tidal carbon dioxide: There were no significant differences in end-tidal carbon 
dioxide % and levels between any of the study days at any time point. The mean 
(SEM) end-tidal C02% levels on completion of each study day were: 
hyperoxia/salbutamol study day 4.6 (0.08)%, hypoxia/salbutamol study day 4.5 
(0.11)%, hyperoxia/placebo study day 4.5 (0.14)% and hypoxia/placebo study day 4.6 
(0 .10)%.
Respiratory rate: There were no significant differences in respiratory rate between 
study days at any time point (data not shown)
Raw data for this chapter is included in the Appendix (tables 27A -  30A)
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9.4 Discussion
Acute hypoxia in-vivo in patients with stable asthma has not in our study altered the 
ability of salbutamol to relax airway smooth muscle. This is in contrast to our in- 
vitro study (chapter 3) in human isolated bronchial rings where acute hypoxia 
significantly attenuated the ability of salbutamol to relax human isolated bronchial 
rings preconstricted with methacholine.
The changes in oxygen saturation that we have observed in our patients would suggest 
that our closed breathing circuit has achieved significant changes in arterial and 
airway oxygen tensions.^ The presence of these changes is also supported by the 
fall in heart rate which we have observed on the study days that our patients inhaled 
oxygen (Fi02 100%).^^  ^ Reduced tonic activity in carotid chemoreceptors in response 
to hyperoxia, suggested by the fall in heart rate we have observed in our study, may 
have led indirectly to alterations in airway tone in our subjects which could 
potentially have influenced our results. An increase in vagal tone while breathing 
100% oxygen may have indirectly caused an increase in airway smooth muscle tone 
significantly affecting the results of our study. We have not observed any differences 
in end-tidal carbon dioxide levels between the study days suggesting that alterations 
in minute ventilation following inspiration of our gas mixtures has not caused 
hypocapnic bronchoconstriction.^^^’^ ^^  Nebuliser output for both the hypoxic and 
hyperoxic gas mixtures was found to be 0.11 mls/min at a flow rate of 6 1/min. This 
had been checked prior to the commencement of the study.
There are several possible explanations for the differences we have observed between 
our in-vitro and in-vivo studies. The human isolated bronchial rings we have used
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were from stable patients undergoing elective thoracic surgery who did not have 
asthma. The lowest inspired oxygen tension used in the in-vivo study was 15% in 
contrast to 4% in the in-vitro study. Previous in-vitro studies have suggested that the 
contractile strength of airway smooth muscle is significantly impaired by profound 
hypoxia. If hypoxic relaxation had occurred in our in-vitro study, one might have 
expected that hypoxia would potentiate the ability of salbutamol to relax smooth 
muscle rather than attenuate it as we have previously observed (chapter 3). That this 
has not occurred suggests that hypoxia has other effects in-vitro^ which may include 
down regulation of B-receptors^^  ^or uncoupling of B-receptors from their regulatory 
G-proteins,^^^ which have offset the direct action of hypoxia on smooth muscle. The 
presence of circulating humoral factors and intact neural innervation in our subjects 
in-vivo^ which hypoxia and hyperoxia may directly affect, further complicates the 
interpretation of our results in this study. Circulating catecholamine levels may affect 
airway tone in-vivo In previous studies using the same closed breathing circuit and 
inspired oxygen tension, we have however shown no significant changes in 
circulating catecholamine levels. It is also worth considering that the concentrations 
of salbutamol used in the organ baths are significantly greater than the cumulative 
doses administered to our patients and this may also explain the differences in our 
findings.
We conclude that acute hypoxia has no effect on salbutamol induced bronchodilation 
in patients with stable asthma when compared to normoxia and hyperoxia.
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FEVl
Patient
No
Age
(years)
Sex absolute value (L) 
pre-sal post-sal
post-sal 
% predicted
Current
treatment
1 44 M 2.14 2.82 83 sal pm, B
2 52 M 2.70 3.15 91 sal pm, B
3 39 M 3.12 3.60 90 sal pm
4 52 M 2.31 2.72 66 sal pm, B
5 34 F 3.02 3.52 106 sal pm, B
6 35 M 3.15 3.80 88 sal pm,B
7 49 M 2.08 2.75 77 sal pm, B, S, Neb
8 36 M 2.85 3.29 98 sal prn
9 29 M 2.94 3.59 79 sal pm, B
10 32 F 2.33 2.73 107 sal pm, B, S
11 29 M 3.34 3.93 87 sal pm, B
12 36 M 2.52 2.97 75 sal prn, B, S, Th
Mean
(SD)
39
(8)
2.71
(0.42)
3.24
(0.44)
87
(11)
Table 9,1: Patient characteristics, sal pm = inhaled salbutamol as required, B = inhaled 
steroid (beclomethasone or budesonide), S = inhaled salmeterol twice daily, Th = oral 
theophylline. Neb = nebulised salbutamol and ipratropium bromide as required, pre-sal = pre- 
salbutamol FEVi, post-sal = post-salbutamol FEVi.
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Fig 9.1 The effect of 3 incremental doses of nebulised salbutamol or placebo on 
absolute change in FEV, (litres) and heart rate (beats per minute) from baseline in 12 
asthmatic patients breathing oxygen tensions of 100% and 15%.
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Fig 9.2 The effect of 3 incremental doses of nebulised salbutamol or placebo on 
oxygen saturation (Sa0 2 %) in 12 asthmatic patients breathing oxygen tensions of 
100% and 15%.
CHAPTER 10 
CONCLUSIONS
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The studies outlined in this thesis have provided some insight into the effects of acute 
alterations in oxygen tension on airway tone following exposure to bronchodilator and 
bronchoconstrictor stimuli both in-vitro in man and in-vivo in patients with asthma. 
Such observations may be of importance in patients with acute exacerbations of 
asthma who as part of their initial management these patients receive high inspired 
oxygen tensions to breathe and both nebulised and intravenous bronchodilators. Our 
studies are the first to have suggested that in-vitro hypoxia significantly attenuates the 
effects of salbutamol, histamine and methacholine in human isolated bronchial rings. 
In patients with asthma hypoxia apparently potentiates the constrictor effect of 
methacholine but has no effect on histamine induced constriction and salbutamol 
induced relaxation of airway tone. These observations might suggest that hypoxia not 
only occurs as a consequence of acute exacerbations of asthma but may itself 
potentiate the constrictor effects of inflammatory mediators which are released during 
such exacerbations, and reduce the effectiveness of bronchodilating drugs such as 
salbutamol to relieve bronchoconstriction.
In-vitro studies
Our initial in-vitro studies were designed to examine the effects of acute alterations in 
oxygen tension on constrictor and dilator stimuli in bronchial rings from man, 
therefore expanding observations we had already made in bovine and rat isolated 
bronchial r i n g s . W e  have shown that the ability of histamine and methacholine to 
constrict airway smooth muscle declines as the ambient oxygen tension falls and that 
this occurs in a linear fashion (chapter3). This observation is in keeping with our 
original findings in rat isolated bronchial rings^  ^pre-constricted with methacholine, 
and also in agreement with several other groups who have reported hypoxic relaxation
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following pharmacological challenge in-vitro in porcine, canine and guinea pig 
bronchial rings/^'^^ It is now widely accepted that in-vitro the ability of airway 
smooth muscle to contract following electrical and pharmacological challenge in a 
hypoxic environment is impaired. The precise mechanism of this effect remains 
u n c l e a r . P o s s i b l e  mechanisms, which have been postulated to promote this 
effect include, failure of mitochondrial function^^'^\ secretion of an epithelial derived 
relaxing factor,^^ an increase in the influx of Ca^ ions into smooth muscle cells^  ^and 
opening of membrane-bound channels. All of these postulated mechanisms 
result from a direct effect of hypoxia on airway smooth muscle and are independent 
of the spasmogen which is used. It would therefore, be interesting to repeat our 
studies in human bronchial rings both with and without intact epithelium and 
following pre-incubation of the airway smooth muscle rings with both Ca^ "^  and 
channel blockers in an attempt to determine the mechanism of hypoxic relaxation in 
human isolated bronchial rings constricted ^vith histamine and methacholine. It 
would also be interesting to examine the effect of hypoxia on a number of other 
spasmogens including carbachol, adenosine and leukotrienes which cause airway 
smooth muscle contraction by other mechanisms. The data from such studies in 
human isolated bronchial rings might provide important evidence to support the 
hypothesis that hypoxic relaxation occurs as a direct effect of hypoxia on airway 
smooth muscle, as seems likely, and is not specific to the spasmogen used.
If hypoxia attenuates the effects of spasmogens on airway smooth muscle tone, one 
would speculate that during acute exacerbations of asthma this action would be 
beneficial rather than harmful. Observations from our own in-vivo studies have in 
fact suggested that if anything hypoxia potentiates methacholine induced
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bronchoconstriction (chapters 6 and 7). This difference is almost certainly due to the 
profoundly different oxygen tensions that have been used in our studies. It will never 
be possible to undertake in-vivo studies using an FiO^ of 4% but as we have suggested 
we could repeat our in-vitro studies using an ambient oxygen tension of 15%. This 
observation would also support our hypothesis that in-vitro profound hypoxia has a 
direct effect on the ability of airway smooth muscle to generate tone, and that this 
effect is independent of the action of any specific spasmogen. We would speculate 
that using a higher O2 tension in-vitro would, like our in-vivo study, show potentiation 
of methacholine induced constriction possibly through release of inflammatory 
m e d i a t o r s . W e  think that hypoxic relaxation in-vitro is not a linear effect but 
occurs below a certain threshold level of hypoxia. We believe that while functional 
in-vitro studies are traditionally carried out in oxygen tensions of 95%, it would be 
interesting to construct cumulative concentration-response curves for histamine and 
methacholine in human bronchial rings at various oxygen tensions between 0% and 
100%. As we have stated it would be particularly interesting to see the effect of an 
oxygen tension of 15% in-vitro.
We have for the purposes of our in-vitro studies used human bronchial rings obtained 
from patients undergoing elective thoracotomy at our own hospital. These patients 
tend to be elderly, current or ex-cigarette smokers and have an underlying pulmonary 
malignancy. The majority of such patients do not have asthma. There is in-vitro 
evidence to suggest that the airways of patients with asthma are hyperresponsive to 
some agonists when compared to airway smooth muscle from healthy controls.
If there exists an intrinsic defect of asthmatic airway smooth muscle then the results 
from our in-vitro studies may not truly reflect what happens in asthmatic airways. It
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is interesting to speculate what results we would obtain if we repeated our in-vitro 
studies using bronchial rings obtained from patients with asthma.
The findings from our in-vitro studies in human bronchial rings are however the 
converse of our earlier observations in bovine bronchial rings whereby hypoxia 
potentiated the constrictor effects of both methacholine and endothelin-1^^"^  ^when 
compared to hyperoxia. These studies were undertaken using the same protocols, 
employed the same oxygen tensions and were performed in the same laboratories 
making this difference difficult to explain. It may simply represent species difference 
although numerous other studies have shown no difference between species and the 
finding of hypoxic relaxation following pharmacological challenge.^^’^ ’^^ ’^^ ’^^  ^ It 
would be interesting to examine the effect of endothelin-1, a putative inflammatory 
mediator in asthma, on human bronchial rings and to determine whether in the 
presence of varying degrees of hypoxia it potentiated airway smooth muscle 
constriction or relaxation. It is possible to speculate that hypoxia as well as having 
direct effects on airway smooth muscle may have effects on specific receptor sites 
and their expression. Any alteration in receptor characteristics might overcome the 
direct effects of hypoxia on intracellular metabolic pathways as a possible 
explanation for the effect of endothelin-1 in bovine isolated bronchial rings. The 
activity or density of endothelin-I receptors may therefore be enhanced by hypoxia. 
This could be further examined using functional antagonists of endothelin-1 receptors 
or looking directly at endothelin-1 receptor densities histologically using specific 
staining techniques.
139
In our second series of in-vitro studies we have suggested that the ability of 
salbutamol to relax airway smooth muscle is significantly attenuated by hypoxia when 
compared to hyperoxia. This observation may have important implications in the 
management of patients with acute severe asthma who are often hypoxaemic and 
receive both nebulised and intravenous salbutamol in an attempt to relieve 
bronchoconstriction. We have already suggested that hypoxia has direct effects on 
airway smooth muscle significantly impairing the ability of cells to generate 
contractile strength. If this were the whole story one might anticipate that hypoxia in 
an additive fashion would potentiate, or at worst have no effect on the ability of 
salbutamol to relax hypoxic airway smooth muscle when compared to normoxia and 
hyperoxia. It seems likely therefore that hypoxia has additional effects on isolated 
airway smooth muscle cells which explain our in-vitro observations. There is 
evidence to suggest that hypoxia, induced by altitude, reduces the density of h- 
adrenergic receptors and reduces intracellular adenylate cyclase levels in rat 
myocardium. As salbutamol causes smooth muscle relaxation by increasing 
intracellular cyclic adenosine monophosphate (cAMP) via activation of adenylate 
cyclase a similar observation in man could explain our in-vitro findings. Interestingly 
the observations by Voelkel et al“  ^occur at levels of hypoxia that a patient suffering 
an exacerbation of asthma might experience. It would therefore be interesting to 
measure B-adrenergic receptor densities and intracellular adenylate cyclase activity in 
airway smooth muscle cells, exposed to varying levels of hypoxia and hyperoxia for 
differing amounts of time, using the techniques described by Voelkel et al.^ ^^  Further 
support for our suggestion that hypoxia attenuates the dilator effect of salbutamol by 
down regulation of B-receptors could be provided by examining the effects of other 
bronchodilators in-vitro which cause smooth muscle relaxation through mechanisms
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which are independent of B-adrenergic receptors. It is clear from our earlier studies in 
bovine isolated bronchial rings that the pattern of smooth muscle relaxation varies 
quite considerably depending on the oxygen tension and bronchodilator which is used 
in-vitroP'^^ It has been postulated that this observation reflects differences in 
second-messenger pathways used by the bronchodilators to induce smooth muscle 
relaxation and the effects that hypoxia has on these pathways.^^ It would therefore be 
worthwhile exploring the effects of hypoxia on airway smooth muscle relaxation in 
bronchial rings incubated with other bronchodilators such as atrial natriuretic peptide 
which causes a rise in cyclic guanosine monophosphate (cGMP) via stimulation of 
particulate guanylate cyclase and isosorbide dinitrate, which also causes a rise cGMP 
but via stimulation of soluble guanylate cyclase.^^
Previous investigators have postulated that salbutamol induced relaxation of airway 
smooth muscle cells is mediated partly by opening of membrane-bound 
channels. There exists in the literature some evidence to suggest that in second and 
third order porcine isolated bronchial rings hypoxia increases the number of 
membrane-bound channels which are held open which could potentially reduce the 
ability of the bronchodilator salbutamol to relax airway smooth muscle cells. ^  This 
observation if applicable in human isolated bronchial rings could explain our own in- 
vitro observations whereby hypoxia attenuated the ability of salbutamol to relax 
human bronchial rings (chapter 3). If in human bronchial rings glibenclamide, a 
potent K^ATP channel blocker, abolished or reduced the effect of hypoxia on 
salbutamol induced airway smooth muscle relaxation this might provide evidence for 
hypoxic opening of membrane-bound channels as a mechanism for our own in- 
vitro findings.
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To complete this series of studies it would be worthwhile considering the effect of 
hypoxia and hyperoxia on airway smooth muscle relaxation following the 
administration of other commonly used bronchodilators. Such observations may have 
important implication in the management of acute severe asthma. Other drugs which 
relax airway smooth muscle and are used in the management of acute severe and life 
threatening asthma, include nebulised ipratropium bromide and intravenous 
theophylline and occasionally intravenous magnesium and ketamine. As we have 
already suggested from our in-vitro findings for histamine, repeating these studies at 
various oxygen tension between 0% and 100% in bronchial rings from patients with 
asthma might provide valuable additional information about the nature of the 
relationship between hypoxia, airway smooth muscle tone and bronchodilators and 
whether or not this relationship is linear.
In conclusion, our first in-vitro studies have suggested that acute hypoxia attenuates 
histamine and methacholine induced constriction of human airway smooth muscle.
We would suggest that this is due to a direct effect of hypoxia on airway smooth 
muscle and is independent of the spasmogen used. The cause of hypoxic relaxation 
however remains controversial and further studies are needed to determine the 
underlying mechanism. We have also concluded that the profound levels of hypoxia 
we have used in our in-vitro studies make it difficult to compare our in-vitro findings 
with those of our in-vivo studies. We have speculated as to the effects, on our results, 
of using both lesser degrees of hypoxia and bronchial rings from patients with asthma. 
We have also suggested that hypoxia inhibits salbutamol induced airway smooth 
muscle relaxation and conclude that this observation may have important implications
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for patients with severe exacerbations of asthma who are admitted to hospital. 
Possible mechanisms for this important finding include reduced density of B- 
adrenergic receptors and alterations in the resting state of membrane-bound 
channels. Further investigation as outlined above may provide important information 
about the mechanism of this effect and the interaction of hypoxia with other 
bronchodilators that have a role in the management of acute severe asthma.
Following review of our initial in-vitro studies we proceeded to investigate the effects 
of acute alterations in inspired oxygen tension on bronchoconstrictor and 
bronchodilator stimuli in patients with asthma. We have used a novel closed 
breathing circuit (chapter 2) to undertake these investigations. Our studies have 
suggested that acute hypoxia in-vivo potentiates the bronchoconstrictor effect of 
methacholine (chapter 6) but not histamine (chapter 7). Hyperoxia does not appear to 
have any effect on methacholine or histamine induced bronchial hyperresponsiveness 
(chapters 5 and 7). The ability of the bronchodilator salbutamol to attenuate airway 
tone in patients with asthma appears to be unaffected by hypoxia or hyperoxia 
(chapters 8 and 9).
Hypoxia in-vivo studies
In our hypoxic in-vivo studies we have examined the effect of breathing low (FiO  ^
15%) inspired oxygen tensions on airway responsiveness to methacholine, histamine 
and salbutamol in patients with stable asthma. In our in-vivo studies we have used a 
novel closed breathing circuit (chapter 2) to induce a moderate level of hypoxaemia 
in our stable asthmatic patients. In our patients all of the airway mucosa and cells 
lining the alveolar air spaces will be exposed to a low oxygen tension (O2 15%). The
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alveolar air spaces are surrounded by a rich plexus of blood vessels derived from the 
pulmonary arterial circulation. As alveolar oxygen levels fall the oxygen tension in 
the pulmonary capilliaries surrounding the alveolar air sacs also falls. Blood from the 
pulmonary capilliaries drains back to the left atrimn via the pulmonary veins. From 
the left atrium blood with a significantly reduced oxygen tension enters into the 
systemic circulation. The cells which constitute the airway walls of our patients, using 
the closed breathing circuit, will be hypoxaemic reflecting the low systemic arterial 
oxygen tension which we have induced.
Previous studies, using multiple inert gas techniques, have shown that in patients with 
asthma ventilation throughout the lungs is uneven and reflects underlying differences 
in small airway calibre. These abnormalities are found in all patients with asthma 
including those who are asymptomatic. In severe asthma, hypoxaemia occurs 
almost exclusively as a consequence of ventilation perfusion mismatch. The
degree of ventilation perfusion mismatch appears related to asthma severity and is 
greatest in those admitted to hospital with hypoxaemia. There is almost no
contribution to hypoxaemia from intrapulmonary shunting or impairment of oxygen 
diffusion across the alveolar capillary membrane. It is well recognised that the 
degree of hypoxaemia in asthma relates poorly to the severity of underlying airflow 
obstruction. Following nebulised and intravenous bronchodilators, measurements 
of airflow obstruction will normalise but hypoxaemia often persists. This would 
suggest that the uneven ventilation seen in patients with asthma occurs as a 
consequence of occlusion of smaller airways rather than larger airways. Occlusion 
of smaller airways with mucus, inflammatory debris and odema fluid results in 
critically reduced ventilation to areas of lung parenchyma which remain perfused.
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This results in significant ventilation perfusion mismatch and subsequent hypoxaemia 
in patients during acute exacerbations of a s t h m a / T h e  mucosa cells lining the 
bronchial tree in these areas will be exposed to a low oxygen tension. In other areas, 
including larger airways and some alveolar air spaces, hyperventilation allied to the 
maintenance of normal airway calibre results in areas with elevated oxygen and 
reduced carbon dioxide tensions. This would suggest that during acute 
exacerbations of asthma airway oxygen tension varies throughout the bronchial tree. 
Alveolar hypoxia occurs in areas with low ventilation. The degree of alveolar 
hypoxia will be variable and relate to the severity of the underlying asthma 
exacerbation and the treatment that a patient has received. In severe exacerbations of 
asthma cardiac output increases and may inadvertently raise perfusion to low 
ventilation areas paradoxically worsening existing hypoxaemia by increasing 
ventilation perfusion mismatch. Hypoxic pulmonary vasoconstriction is a reflex 
which occurs around areas of low ventilation where alveolar hypoxia is greatest. 
Hypoxic pulmonary vasoconstriction acts to reverse ventilation perfusion mismatch 
and improve hypoxaemia. The presence of hypoxic pulmonary vasoconstriction 
further complicates direct comparisons between hypoxaemia induced by our closed 
breathing circuit and hypoxaemia that occurs in patients suffering an acute 
exacerbation of asthma.
It is important to recognise that patients using our closed breathing circuit are 
therefore both hypoxic (low airway oxygen tension) and hypoxaemic (low systemic 
arterial oxygen tension). This should be contrasted with patients suffering an acute 
exacerbation of asthma where although alveolar hypoxia occurs in some areas much 
of the bronchial tree is exposed to normal or even increased oxygen tensions due to
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hyperventilation. The mechanism of hypoxaemia in patients with acute exacerbations 
of asthma is therefore different when compared to patients using our closed breathing 
circuit where the entire bronchial epithelium is exposed to a low oxygen tension. 
Airway smooth muscle, which derives its blood supply from the systemic circulation, 
is exposed to hypoxaemia in both groups of patients and is therefore not significantly 
different. Our closed breathing circuit therefore compares favourably with our in- 
vitro studies where bronchial rings are exposed to a low oxygen tension but we must 
however be cautious in extending the results of our in-vivo studies to patients with 
acute exacerbations of asthma complicated by hypoxaemia.
The most significant finding from our in-vivo studies is the observation that 
methacholine induced bronchoconstriction is potentiated and histamine induced 
bronchoconstriction unaffected, by hypoxia (FiOj 15%) in patients with mild asthma 
(chapters 5, 6 and 7). Hypoxia does not appear to impair the ability of salbutamol to 
relax airway smooth muscle. Potentiation of the constrictor effects of methacholine 
by hypoxia and hypoxaemia may have relevance to patients admitted to hospital with 
acute exacerbations of asthma and might suggest that hypoxaemia occurs not only as 
a consequence of acute asthma but may also act to amplify the constrictor effects of 
inflammatory mediators released during such exacerbations.
This observation differs from our in-vitro finding of attenuation of methacholine 
induced constriction by hypoxia in human isolated bronchial rings. It seems likely 
that hypoxia has diverse actions which occur at different ambient oxygen tensions. 
These actions may lead to elevated inflammatory mediator release,impainnent of 
mitochondrial function,^^’^  ^reduced density of cell membrane receptors^ and
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inhibition of entry into cells/^ We believe that differences between our in-vitro 
and in-vivo studies reflect different actions of oxygen at different ambient oxygen 
tensions. In-vivo it seems likely that mediator release potentiates methacholine 
induced bronchoconstriction. We believe that in-vivo as inspired oxygen tension falls 
hypoxaemia causes increased sympathetic activity and reduced airway tone via neural 
innervation. This manifests itself as an elevated heart rate. At profound levels of 
hypoxia, as found in our in-vitro studies, there may be impairment of mitochondrial 
function,^^’^  ^release of an epithelial relaxing factor,^^ reduction in receptor 
densities^ or impairment of second messenger pathways to explain attenuation of 
methacholine and histamine induced constriction and salbutamol induced relaxation 
of airway tone.
Our observation of potentiation of methacholine induced bronchoconstriction in 
patients with asthma is not new but contributes significantly to the literature where 
there have previously been a number of conflicting reports. Our observations are in 
agreement with Denjean et af^ whose group suggested that hypoxia potentiates 
methacholine induced bronchoconstriction in patients with asthma but disagrees with 
Tam et a/^^ who were unable to show a similar effect in patients inspiring dry gases 
as a non-specific bronchial challenge. There is perhaps more agreement in animal 
studies where several authors have reported^^’^ ’^^  ^that hypoxia potentiates non­
specific bronchial reactivity in-vivo in animals. What perhaps remains more 
controversial are the potential mechanisms of this effect. Several different 
mechanisms have been suggested for hypoxia having indirect influences on airway 
tone including reflex neural constriction following stimulation of carotid 
chemoreceptors,^^ a direct action of hypoxia on smooth muscle cells causing
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constriction,^^ local release of inflammatory mediators^^ and release of circulating 
humoral factors which may then have indirect influences on airway tone.
One of the more likely possibilities is the release of local inflammatory mediators 
from cells by hypoxia. D’Brot and Ahmed^^ were able to demonstrate that hypoxic 
potentiation of carbachol and histamine induced bronchoconstriction in sheep was 
abolished using cromolyn sodium,^^ a mast cell stabiliser and FPL 57231,^^ a novel 
leukotriene receptor antagonist. To investigate the potential mechanism of hypoxic 
constriction in patients with asthma it would be interesting to examine samples from 
the airways of the lower respiratory tract both before and after methacholine 
challenge in patients breathing a hypoxic gas mixture when compared to a control 
group breathing air. Samples can now readily be obtained from the lower airways 
using induced sputum techniques. This would allow direct measurement of a number 
of inflammatory mediators including histamine, leukotrienes and some cytokines 
which may be released in response to airway hypoxia and arterial hypoxaemia. If the 
release of local inflammatory mediators were the cause of hypoxic potentiation of 
bronchial reactivity then such observations might provide support for the use of novel 
asthma therapies in patients with hypoxaemia complicating acute exacerbations of 
asthma. For example the new leukotriene receptor antagonists now available may 
find a role in the management of acute exacerbations of asthma complicated by 
hypoxaemia.
We were acutely aware during the design of our hypoxic studies that hypoxaemia 
might have effects on circulating humoral factors which could influence airway tone 
and that such an effect might confound our results.^ "^  We have for this reason
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measured serum catecholamine levels in our studies and found them to be no different 
following inhalation of a hypoxic gas mixture suggesting that changes in circulating 
adrenaline and noradrenaline levels have not influenced our results. However it 
remains possible that other humoral factors released in response to hypoxia may have 
influenced our results. Millar^ "^  ^suggested that the renin angiotensin system may be 
activated by hypoxia^ "^  ^leading to a rise in serum angiotensin levels. She also 
observed in her studies that angiotensin potentiates methacholine induced 
bronchoconstriction in patients with mild asthma. A rise in angiotensin levels in 
our studies in response to hypoxia could explain our results. It may be appropriate in 
future hypoxic studies to measure plasma levels of other peptides and hormones 
which might have influences on airway tone including renin, angiotensin, natriuretic 
peptides, histamine and endothelin.^"  ^ Once again the detection of a circulating 
humoral factor which acts synergistically with hypoxia to increase airway tone during 
an acute exacerbation of asthma raises the possibility of developing novel treatments 
in patients with acute exacerbations of asthma associated with hypoxaemia.
It has been suggested by some authors that acute hypoxaemia causes stimulation of 
carotid and peripheral chemoreceptors which indirectly increases airway tone by 
stimulation of airway vagal nerves.^^’^  ^ Vidruk and Sorkness^^ demonstrated that 
combined cervical vagotomy and bilateral transection of the superior laryngeal nerve 
abolished increased airway reactivity caused by hypoxia in tracheal segments of intact 
dogs that had inhaled histamine. In a similar study Denjean et al^  ^ suggested that 
surgical chemodenervation abolished the increased methacholine bronchial reactivity 
they had observed in sheep inhaling a hypoxic gas mixture. We would suggest that 
stimulation of carotid and arterial chemoreceptors is unlikely to have influenced the
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results of our hypoxic studies as we have not observed any changes in heart rate or 
end-tidal CO2 levels in our patients exposed to hypoxia which one might anticipate 
would accompany any chemoreceptor stimulation/^’^ I t  is interesting to note 
that in the study by Tam et a/^^ they were unable to show an increase in bronchial 
reactivity in their patients inhaling eucapnic dry air with an inspired oxygen tension of 
8%. They however found a dramatic increase in the heart rate of their patients 
suggesting a significant increase in sympathetic output. This increase in sympathetic 
output almost certainly had indirect effects on airway tone in their patients which 
influenced their results. Vidruk and Sorkness^^ in their study on dogs lowered 
arterial oxygen tension to 45 mm Hg It is likely that at this level of hypoxaemia they 
had also caused stimulation of carotid chemoreceptors which may indirectly have 
influenced their results. There is no account in their paper of heart rate responses in 
the mongrel dogs that they studied.
Hypoxia may also have direct effects on airway smooth muscle tone. Studies in man 
have given rather conflicting results. Some authors have suggested that hypoxia 
causes bronchoconstriction/^’^  ^others have shown no change in airway tone^^’^  ^and 
more recently some have even suggested bronchodilation occurs. In the presence 
of such conflicting observations it seems unlikely that hypoxia induces any clinically 
significant change in airway tone and certainly not of a magnitude which is likely to 
have influenced our results. We have not shown any change in FEVi measured 10 
minutes after inhaling an inspired oxygen tension of 15% in any of our in-vivo 
studies, an observation that lends further support to our conclusion that hypoxia has 
not had any significant direct effect on airway tone in our patients.
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If as we are suggesting hypoxia increases airway reactivity by indirect means, then 
our observation that hypoxia does not potentiate histamine induced 
bronchoconstriction must be regarded as surprising. This difference in observations 
has occurred despite using the same inspired oxygen tension, study design and 
breathing circuit in both studies. This is an intriguing observation that is difficult to 
account for. Specific receptors on airway smooth muscle cells bind methacholine and 
histamine. This interaction results in the production of inositol phospholipid 
metabolites via a complex biochemical pathway. Inositol 1,4,5 triphosphate, an 
intracellular second messenger, causes release of intracellular calcium ions which 
promotes smooth muscle contraction. One could speculate that hypoxia has a 
specific effect on acetylcholine receptors which when methacholine binds to them 
augments smooth muscle contraction, perhaps via an effect on regulatory G-proteins. 
It would seem that this effect does not occur with histamine receptors in-vivo. The 
results from our study examining the effect of hypoxia on histamine induced 
bronchoconstriction have shown a trend towards increased bronchial reactivity with 
hypoxaemia. It may well be that a larger study would have converted this trend to 
statistical significance. However this observation raises the importance of examining 
the effect of hypoxaemia on a number of different spasmogens in order to determine 
whether the effect is specific to methacholine or occurs with constrictor agents that 
work via other mechanisms. It would be interesting to see the effect of hypoxaemia 
on inhaled endothelin-1, leukotrienes and adenosine.
We have also examined the effect of hypoxia on salbutamol induced relaxation of 
airway smooth muscle in patients with asthma. Following observations from our in- 
vitro studies we had hypothesised that hypoxia might attenuate the ability of
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salbutamol to relax airway smooth muscle. We were however acutely aware that our 
in-vitro studies had used much more profound levels of hypoxaemia and much higher 
concentrations of salbutamol than we would expect to find in patients with asthma, 
and that this might directly affect the results of our in-vivo studies. We had suggested 
as possible mechanisms for this effect, down regulation of B-receptors,opening of 
membrane bound channels, and as we have already suggested release of local 
inflammatory mediators. Results from our study have not shown attenuation of 
airway relaxation following inhaled salbutamol by hypoxia. It is possible that a larger 
study would have achieved a statistically significant result. However it is also 
possible that the duration of our study was inadequate to allow sufficient down 
regulation of B-receptors or opening of membrane bound channels for the effect to 
have become apparent. It would be worthwhile repeating the study with a longer 
period of hypoxaemia prior to the administration of salbutamol. The effect of 
hypoxia on other commonly used bronchodilators, with various mechanisms of 
action, in acute exacerbations of asthma should also be considered. This would 
include studies examining the effect of hypoxia on anti-cholinergic drugs, intravenous 
theophyllines, natriuretic peptides and magnesium.
We would conclude therefore that acute hypoxia potentiates methacholine induced 
bronchoconstriction in-vivo and that this may be relevant in patients with acute 
exacerbations of asthma admitted to hospital. We conclude that this effect is likely to 
be mediated by release of local inflammatory mediators, or release of circulating 
humoral factors in response to hypoxia and that further studies attempting to 
determine the mechanism of this effect may lead to the development of novel 
treatments for patients admitted to hospital with acute exacerbation of asthma
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complicated by hypoxaemia. We have been unable to demonstrate any effect of 
hypoxia on salbutamol induced relaxation of airway tone in patients with asthma.
Hyperoxia in-vivo studies
We have been unable to show any significant effect of hyperoxia (FiO  ^100%) on 
methacholine (chapter 5) and histamine (chapter 7) induced bronchoconstriction or 
salbutamol induced relaxation (chapter 8) of airway smooth muscle in patients with 
asthma. These studies were prompted by in-vitro observations in our own laboratory 
that hyperoxia protected against methacholine and endothelin-1 induced constriction 
in bovine isolated bronchial rings.
The rise in oxygen saturation, fall in heart rate and end-tidal 00^% levels which we 
had observed our normal subjects (chapter 4) suggested to us that our novel closed 
breathing circuit was capable of producing and maintaining a high airway and arterial 
oxygen tension.^^’^ ^^ ’^ ^^  We had decided to use an inspired oxygen tension of 100% in 
our in-vivo studies to mimic the oxygen tensions which had been used in-vitro. It is 
likely that the fall in heart rate that we have observed on our hyperoxic study days has 
occurred due to reduced tone in carotid chemoreceptors which has caused increased 
vagal stimulation. This increase in vagal stimulation may have had indirect effects 
on airway tone and confounded the results of our hyperoxic studies. Electrical 
stimulation of vagal motor efferents causes bronchoconstriction via muscarinic 
receptors on airway smooth muscle. If hyperoxia has indirectly caused 
bronchoconstriction in our patients this could certainly have confounded the results in 
our studies examining the effect of hyperoxia on salbutamol induced relaxation and 
both methacholine and histamine induced constriction of airway smooth muscle in
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patients with asthma (chapters 5, 7 and 8). This effect would also explain the 
differences between our in-vitro and in-vivo findings. Bronchial rings deprived of 
their normal neural innervation and circulating humoral factors can derive a 
protective effect from hyperoxia that does not translate into our in-vivo studies. This 
observation suggests that an indirect effect of hyperoxia on airway smooth muscle has 
occurred in our in-vivo studies.
Against this argument is the observation that FEVi after inhaling oxygen (FiO  ^100%) 
for 10 minutes in our studies was not significantly different from the measurements 
made on the normoxic and hypoxic study days suggesting that any effect was 
minimal. There is very little literature concerning the effect of acute hyperoxia on 
airway tone in patients with asthma, and what little there is has suggested that 
hyperoxia has no effect on airway tone.^°^’^ °^  In studies on normal subjects, periods 
of hyperoxia of about 12 hours can cause a fall in FVC.^^  ^ Clearly the duration that 
this takes to develop would suggest that it is not mediated by vagal nerves. We must 
conclude therefore that hyperoxia may have had indirect effects on airway tone in our 
patients, and that further investigation of this area would require detailed examination 
of the neural and humoral effects of hyperoxia on airway tone in patients with asthma 
with detailed measurements of lung function using different inspired oxygen tensions 
prior to the administration of any challenge tests.
In summary this thesis has started to explore the effects of acute alterations in 
ambient oxygen tension on the interaction between constrictor and dilator stimuli and 
airway smooth muscle in-vitro in man and in-vivo in patients with asthma. This is 
clearly a complex interaction and we have suggested that that oxygen has different
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effects depending on the ambient tension. We have suggested that hypoxia may 
attenuate the ability of salbutamol to relax airway smooth muscle in-vitro and 
potentiate methacholine induced bronchoconstriction in-vivo. These observations 
may be of particular relevance to patients with acute exacerbations of asthma 
complicated by hypoxaemia who as part of their management inhale high inspired 
oxygen tensions and receive both nebulised and intravenous bronchodilators. Further 
investigation as outlined in this conclusion may determine the mechanisms of these 
effects and lead to the development of novel asthma therapies for patients suffering 
acute exacerbations of asthma complicated by hypoxaemia.
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